US5688666A
(en)
*
|
1988-10-28 |
1997-11-18 |
Genentech, Inc. |
Growth hormone variants with altered binding properties
|
US5534617A
(en)
*
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US5350836A
(en)
*
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
US5723286A
(en)
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
EP0564531B1
(de)
*
|
1990-12-03 |
1998-03-25 |
Genentech, Inc. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
JP3672306B2
(ja)
|
1991-04-10 |
2005-07-20 |
ザ スクリップス リサーチ インスティテュート |
ファージミドを使用するヘテロ二量体受容体ライブラリー
|
EP0586549B1
(de)
|
1991-05-10 |
2000-09-20 |
Genentech, Inc. |
Auswählen von agonisten und antagonisten von liganden
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
DE69230142T2
(de)
*
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
ATE408012T1
(de)
|
1991-12-02 |
2008-09-15 |
Medical Res Council |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5874400A
(en)
*
|
1993-07-26 |
1999-02-23 |
Cor Therapeutics |
Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
|
EP0741783B1
(de)
|
1993-12-30 |
2009-03-18 |
President And Fellows Of Harvard College |
"hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
|
US6406855B1
(en)
|
1994-02-17 |
2002-06-18 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US5837458A
(en)
*
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6335319B1
(en)
*
|
1994-11-15 |
2002-01-01 |
Metabolic Pharmaceuticals, Inc. |
Treatment of obesity
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6475806B1
(en)
|
1995-06-07 |
2002-11-05 |
Praecis Pharmaceuticals, Inc. |
Anchor libraries and identification of peptide binding sequences
|
DE122006000003I2
(de)
*
|
1995-09-21 |
2011-01-13 |
Genentech Inc |
Varianten des menschlichen wachstumshormons
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
NZ322175A
(en)
*
|
1995-11-10 |
1999-02-25 |
Elan Corp Plc |
Peptides which enhance transport across tissues and methods of identifying the same
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
AU2531397A
(en)
*
|
1996-03-21 |
1997-10-10 |
President And Fellows Of Harvard College |
Enantiomeric screening process, and compositions therefor
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6361938B1
(en)
|
1996-11-08 |
2002-03-26 |
Elan Corporation, Plc |
Peptides which enhance transport across tissues and methods of identifying and using the same
|
US20070185032A1
(en)
*
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6497874B1
(en)
|
1997-02-05 |
2002-12-24 |
Maardh Sven |
Recombinant phages
|
AU7137398A
(en)
|
1997-04-16 |
1998-11-11 |
Millennium Pharmaceuticals, Inc. |
Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
|
US6306826B1
(en)
|
1997-06-04 |
2001-10-23 |
The Regents Of The University Of California |
Treatment of heart failure with growth hormone
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
*
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US7378506B2
(en)
|
1997-07-21 |
2008-05-27 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
US6639050B1
(en)
|
1997-07-21 |
2003-10-28 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
WO1999006587A2
(en)
|
1997-08-01 |
1999-02-11 |
Morphosys Ag |
Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
|
GB9723955D0
(en)
*
|
1997-11-14 |
1998-01-07 |
Generic Biolog Limited |
Improvements in or relating to detection of molecules in samples
|
GB2334580B
(en)
*
|
1997-11-14 |
2002-12-18 |
Generic Biolog Ltd |
Improvements in or relating to detection of exogenously administered polypeptides
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
ES2305608T3
(es)
|
1997-11-21 |
2008-11-01 |
Genentech, Inc. |
Antigenos tipo a-33 y sus utilizaciones farmacologicas.
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US7056517B2
(en)
|
1998-04-13 |
2006-06-06 |
The Forsyth Institute |
Glucosyltransferase immunogens
|
US7163682B2
(en)
|
1998-04-13 |
2007-01-16 |
The Forsyth Institute |
Glucan binding protein and glucosyltransferase immunogens
|
IL140918A0
(en)
*
|
1998-07-27 |
2002-02-10 |
Genentech Inc |
Improved transformation efficiency in phage display through modification of a coat protein
|
US6387888B1
(en)
*
|
1998-09-30 |
2002-05-14 |
American Foundation For Biological Research, Inc. |
Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
|
US6485972B1
(en)
|
1998-10-15 |
2002-11-26 |
President And Fellows Of Harvard College |
WNT signalling in reproductive organs
|
US6420110B1
(en)
|
1998-10-19 |
2002-07-16 |
Gpc Biotech, Inc. |
Methods and reagents for isolating biologically active peptides
|
CA2348835A1
(en)
*
|
1998-10-28 |
2000-05-04 |
Cornell Research Foundation, Inc. |
Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
US6696063B1
(en)
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
EP1141314A2
(de)
*
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
ES2299276T3
(es)
*
|
1998-12-31 |
2008-05-16 |
Novartis Vaccines And Diagnostics, Inc. |
Polipeptidos env del vih modificados.
|
ES2234560T3
(es)
|
1999-01-06 |
2005-07-01 |
Genentech, Inc. |
Variante mutante del factor de crecimiento de tipo insulina (igf-i).
|
IL143834A0
(en)
|
1999-01-06 |
2002-04-21 |
Genentech Inc |
Insulin-like growth factor (igf) i mutant variants
|
AU3382800A
(en)
|
1999-02-26 |
2000-09-14 |
Millennium Pharmaceuticals, Inc. |
Secreted proteins and uses thereof
|
EP1161451A4
(de)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
Menschliches alpha-endokin und verfahren zu seiner verwendung
|
EP1119368A2
(de)
|
1999-03-03 |
2001-08-01 |
Biogen, Inc. |
Verfahren zür modulierung des fettstoffwechsels und lagerung
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
CA2796140A1
(en)
|
1999-03-25 |
2000-09-28 |
Jochen Salfeld |
Human antibodies that bind human il-12 and methods for producing
|
WO2000058521A2
(en)
*
|
1999-03-31 |
2000-10-05 |
Rosetta Inpharmatics, Inc. |
Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
EP1696037A3
(de)
*
|
1999-05-05 |
2007-01-24 |
Phylogica Limited |
Isolierung von biologischen Modulatoren aus Bibliotheken mit biologisch vielfältigen Genfragmenten
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
US7270969B2
(en)
*
|
1999-05-05 |
2007-09-18 |
Phylogica Limited |
Methods of constructing and screening diverse expression libraries
|
US6221597B1
(en)
|
1999-05-21 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6197517B1
(en)
|
1999-05-21 |
2001-03-06 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US6200803B1
(en)
|
1999-05-21 |
2001-03-13 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
DE60020366T2
(de)
*
|
1999-06-14 |
2006-02-02 |
Genentech Inc., San Francisco |
Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage
|
US20030166003A1
(en)
*
|
1999-06-14 |
2003-09-04 |
Cochran Andrea G. |
Structured peptide scaffold for displaying turn libraries on phage
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
ES2327382T3
(es)
|
1999-07-20 |
2009-10-29 |
Morphosys Ag |
Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
DE19943743C2
(de)
*
|
1999-09-03 |
2002-02-07 |
Jerini Biotools Gmbh |
Verfahren zur Identifizierung von Bindungspartnern mit positions-spezifischen Arrays
|
KR100840033B1
(ko)
*
|
1999-10-20 |
2008-06-19 |
제넨테크, 인크. |
T 헬퍼 세포 매개 질환의 치료를 위한 t 세포 분화의 조절
|
US20060073509A1
(en)
*
|
1999-11-18 |
2006-04-06 |
Michael Kilpatrick |
Method for detecting and quantitating multiple subcellular components
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
JP2003516755A
(ja)
*
|
1999-12-15 |
2003-05-20 |
ジェネンテック・インコーポレーテッド |
ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
|
US20020004247A1
(en)
*
|
1999-12-23 |
2002-01-10 |
Genentech, Inc. |
Assay method
|
ATE361934T1
(de)
|
1999-12-30 |
2007-06-15 |
Harvard College |
Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1
|
SK12942002A3
(sk)
|
2000-02-10 |
2003-05-02 |
Abbott Laboratories |
Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
|
US6436677B1
(en)
|
2000-03-02 |
2002-08-20 |
Promega Corporation |
Method of reverse transcription
|
US6632645B1
(en)
|
2000-03-02 |
2003-10-14 |
Promega Corporation |
Thermophilic DNA polymerases from Thermoactinomyces vulgaris
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
EP1832599A3
(de)
|
2000-04-12 |
2007-11-21 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
EP2199393B1
(de)
*
|
2000-04-17 |
2012-10-31 |
Dyax Corp. |
Verfahren zur Einrichtung von Bibliotheken für genetische Verpackungen unterschiedlicher Familien von Peptiden
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
DE60118935D1
(de)
*
|
2000-04-24 |
2006-05-24 |
Univ Yale New Haven |
Dna & protein bindende miniatur proteine
|
US7495070B2
(en)
*
|
2000-04-24 |
2009-02-24 |
Yale University |
Protein binding miniature proteins
|
ATE389416T1
(de)
|
2000-05-16 |
2008-04-15 |
Genentech Inc |
Behandlung von knorpelerkrankungen
|
US6573370B1
(en)
|
2000-05-19 |
2003-06-03 |
Regents Of The University Of Michigan |
PON3 and uses thereof
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001275378A1
(en)
|
2000-06-08 |
2001-12-17 |
The Center For Blood Research, Inc. |
Methods and compositions for inhibiting immunoglobulin-mediated reperfusion inj ury
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
NZ522700A
(en)
|
2000-06-16 |
2006-02-24 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
CA2414331C
(en)
|
2000-06-28 |
2011-11-29 |
Genetics Institute, Llc. |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
KR20030016310A
(ko)
*
|
2000-06-28 |
2003-02-26 |
브리스톨-마이어스스퀴브컴파니 |
선택적 안드로겐 수용체 조절제, 및 그의 확인, 고안 및사용 방법
|
EP2386575A3
(de)
|
2000-06-29 |
2011-11-30 |
Abbott Laboratories |
Antikörper mit Doppelspezifität und Verfahren zu deren Herstellung und Benutzung
|
US7176037B2
(en)
*
|
2000-07-13 |
2007-02-13 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US6951947B2
(en)
*
|
2000-07-13 |
2005-10-04 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
AU2001277648A1
(en)
|
2000-07-14 |
2002-04-15 |
Cropdesign N.V. |
Plant cyclin-dependent kinase inhibitors
|
US6878861B2
(en)
|
2000-07-21 |
2005-04-12 |
Washington State University Research Foundation |
Acyl coenzyme A thioesterases
|
JP2004509078A
(ja)
|
2000-07-27 |
2004-03-25 |
ジェネンテック・インコーポレーテッド |
Apo−2LレセプターアゴニストとCPT−11の相乗作用
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
CA2418960A1
(en)
|
2000-08-07 |
2002-02-14 |
Inhale Therapeutic Systems, Inc. |
Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
ATE552859T1
(de)
*
|
2000-09-13 |
2012-04-15 |
Praecis Pharm Inc |
Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
AU2002214545B2
(en)
|
2000-09-26 |
2008-04-03 |
Genentech, Inc. |
IGE receptor antagonists
|
US7393532B1
(en)
|
2000-10-18 |
2008-07-01 |
Genentech, Inc. |
Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US6841359B2
(en)
*
|
2000-10-31 |
2005-01-11 |
The General Hospital Corporation |
Streptavidin-binding peptides and uses thereof
|
WO2002046208A2
(en)
|
2000-11-01 |
2002-06-13 |
Elusys Therapeutics, Inc. |
Method of producing biospecific molecules by protein trans-splicing
|
EP2316976A1
(de)
|
2000-11-28 |
2011-05-04 |
Wyeth LLC |
Expressionsanalyse von FKBP Nukleinsäuren und Polypeptiden, die zur Diagnose und Behandlung von Prostatakrebs geeignet sind
|
JP2004526426A
(ja)
|
2000-11-28 |
2004-09-02 |
ワイス |
前立腺癌の診断および治療に有用なkiaa核酸およびポリペプチドの発現分析
|
AU1994402A
(en)
|
2000-11-28 |
2002-06-11 |
Mediummune Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
WO2002046238A2
(en)
*
|
2000-12-05 |
2002-06-13 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
JP4280803B2
(ja)
*
|
2000-12-08 |
2009-06-17 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
慢性リンパ性白血病細胞株および抗体を産生するためのその使用
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
DK1355919T3
(da)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
|
DK1360288T3
(da)
*
|
2000-12-18 |
2011-06-14 |
Dyax Corp |
Fokuserede biblioteker af genetiske pakker
|
CA2447832C
(en)
*
|
2000-12-22 |
2012-09-25 |
Jamshid Tanha |
Phage display libraries of human vh fragments
|
EP1355666B1
(de)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Verwendung von "repulsive guidance molecule" (rgm) und von dessen modulatoren
|
CA2433800C
(en)
|
2001-01-05 |
2016-09-13 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
EP1366058B1
(de)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
EP1377664A2
(de)
|
2001-02-23 |
2004-01-07 |
DSM IP Assets B.V. |
Gene, die für proteolytische enzyme von aspargilli kodieren
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
ES2360205T3
(es)
|
2001-03-02 |
2011-06-01 |
Agennix Ag |
Sistema de ensayo de tres híbridos.
|
CA2342376C
(en)
*
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
MXPA03008454A
(es)
|
2001-03-22 |
2004-06-30 |
Abbott Gmbh & Co Kg |
Animales transgenicos que expresan anticuerpos especificos para genes de interes y usos de los mismos.
|
BR0208637A
(pt)
|
2001-04-02 |
2004-12-07 |
Wyeth Corp |
Pd-1, um receptor para b7-4, e usos dos mesmos
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
CN1636062A
(zh)
|
2001-04-16 |
2005-07-06 |
惠氏控股公司 |
编码多肽抗原的新肺炎链球菌可读框及其应用
|
US6914123B2
(en)
|
2001-04-17 |
2005-07-05 |
Genentech, Inc. |
Hairpin peptides with a novel structural motif and methods relating thereto
|
US7244853B2
(en)
|
2001-05-09 |
2007-07-17 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
DK1572874T3
(da)
|
2001-05-25 |
2013-12-16 |
Human Genome Sciences Inc |
Antistoffer, der immunospecifikt binder til TRAIL receptorer
|
WO2002098280A2
(en)
*
|
2001-06-04 |
2002-12-12 |
Ikonisys Inc. |
Method for detecting infectious agents using computer controlled automated image analysis
|
US20030148380A1
(en)
*
|
2001-06-05 |
2003-08-07 |
Belcher Angela M. |
Molecular recognition of materials
|
US20030113714A1
(en)
*
|
2001-09-28 |
2003-06-19 |
Belcher Angela M. |
Biological control of nanoparticles
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20050164515A9
(en)
*
|
2001-06-05 |
2005-07-28 |
Belcher Angela M. |
Biological control of nanoparticle nucleation, shape and crystal phase
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
EP2000148A1
(de)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Prostatakarzinom
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
BR0210593A
(pt)
|
2001-06-22 |
2007-01-02 |
Pioneer Hi Bred Int |
polinucleotìdeos de defensina e métodos de uso
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
EP2280074A3
(de)
*
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
DE10135039C1
(de)
*
|
2001-07-18 |
2003-03-13 |
Nemod Immuntherapie Ag |
Verfahren zur Isolierung großer Varianzen spezifischer Moleküle für ein Zielmolekül aus Phagemid-Gen-Bibliotheken
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
KR100458083B1
(ko)
*
|
2001-08-29 |
2004-11-18 |
주식회사 아이지세라피 |
파아지 디스플레이 라이브러리로부터 특정 이종 단백질의효율적인 분리를 위한 개선된 헬퍼 파아지 시스템
|
US20030170614A1
(en)
*
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
EP1427806A4
(de)
*
|
2001-08-31 |
2006-04-26 |
Chiron Corp |
Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
|
CA2492823A1
(en)
*
|
2001-09-14 |
2003-03-27 |
Martin F. Bachmann |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
NZ531674A
(en)
|
2001-09-18 |
2009-03-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
US20030073104A1
(en)
*
|
2001-10-02 |
2003-04-17 |
Belcher Angela M. |
Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2002361385B2
(en)
|
2001-12-18 |
2009-11-19 |
Centre National De La Recherche Scientifique Cnrs |
Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
US7087418B2
(en)
|
2001-12-19 |
2006-08-08 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
WO2005077042A2
(en)
|
2004-02-09 |
2005-08-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2277910A1
(de)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin Fusionsproteine
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
JP2005523888A
(ja)
*
|
2002-01-03 |
2005-08-11 |
ザ スクリプス リサーチ インスティテュート |
癌関連エピトープ
|
JP2005523688A
(ja)
*
|
2002-01-18 |
2005-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
タンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
|
WO2003104428A2
(en)
*
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7094579B2
(en)
|
2002-02-13 |
2006-08-22 |
Xoma Technology Ltd. |
Eukaryotic signal sequences for prokaryotic expression
|
WO2003073909A2
(en)
|
2002-03-01 |
2003-09-12 |
Bayer Corporation |
Assays to monitor levels of epidermal growth factor receptor (egfr) extracellular domain (ecd) in cancer patients
|
EP1489968B1
(de)
*
|
2002-03-01 |
2009-02-18 |
Siemens Healthcare Diagnostics Inc. |
Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
|
EP1572149A2
(de)
|
2002-03-07 |
2005-09-14 |
The Forsyth Institute |
Immunogenität von glucan-bindungsprotein
|
CA2480052A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US7745192B2
(en)
|
2002-04-03 |
2010-06-29 |
Venomics Pty Limited |
Prothrombin activating protein
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
JP4511342B2
(ja)
|
2002-05-21 |
2010-07-28 |
ディーエスエム アイピー アセッツ ビー.ブイ. |
新規なホスホリパーゼおよびその使用
|
EP2305710A3
(de)
*
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
CA2488441C
(en)
*
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
WO2003106640A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Case Western Reserve University |
Cell targeting methods and compositions
|
CA2490004A1
(en)
|
2002-06-20 |
2003-12-31 |
Board Of Trustees Operating Michigan State University |
Plastid division and related genes and proteins, and methods of use
|
PT1523496E
(pt)
|
2002-07-18 |
2011-09-29 |
Merus B V |
Produção de misturas de anticorpos de forma recombinante
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US20040219142A1
(en)
|
2002-07-19 |
2004-11-04 |
Abbott Laboratories S.A. |
Treatment of skin and nail disorders using TNFalpha inhibitors
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
DK1534736T3
(da)
|
2002-08-10 |
2010-09-20 |
Biogen Idec Inc |
Nogo-receptorantagonister
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
EP2371389A3
(de)
|
2002-08-14 |
2012-04-18 |
MacroGenics, Inc. |
FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
|
US7550280B2
(en)
|
2002-08-19 |
2009-06-23 |
Dsm Ip Assets B.V. |
Lipases and uses thereof
|
DE10238846A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Nemod Immuntherapie Ag |
Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
|
AU2003250518A1
(en)
|
2002-08-20 |
2004-03-11 |
Yeda Research And Development Co. Ltd. |
Akap84 and its use for visualization of biological structures
|
ATE519862T1
(de)
|
2002-08-20 |
2011-08-15 |
Millennium Pharm Inc |
Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
|
CA2496925A1
(en)
*
|
2002-08-29 |
2004-03-11 |
Genentech, Inc. |
Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
|
EP2181711A1
(de)
|
2002-09-04 |
2010-05-05 |
Biopolymer Engineering, Inc. |
Krebstherapie mit ganzen Glukan-Teilchen und Antikörpern
|
ATE466085T1
(de)
*
|
2002-09-09 |
2010-05-15 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
US20050064508A1
(en)
|
2003-09-22 |
2005-03-24 |
Semzyme |
Peptide mediated synthesis of metallic and magnetic materials
|
DE60335957D1
(de)
|
2002-10-08 |
2011-03-17 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
|
AU2003304238A1
(en)
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
PL377769A1
(pl)
*
|
2002-10-09 |
2006-02-20 |
Rinat Neuroscience Corp. |
Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
|
JP4988201B2
(ja)
|
2002-10-16 |
2012-08-01 |
ユーロ−セルティーク エス.エイ. |
細胞結合性ca125/o772pに結合する抗体およびその使用方法
|
EP1578799B8
(de)
*
|
2002-12-02 |
2011-03-23 |
Amgen Fremont Inc. |
Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
|
US7056702B2
(en)
*
|
2002-12-16 |
2006-06-06 |
Kimberly Clark Co |
Detecting lipocalin
|
NZ540879A
(en)
*
|
2002-12-23 |
2008-08-29 |
Rinat Neuroscience Corp |
Methods for treating taxol-induced sensory neuropathy
|
WO2004058968A1
(de)
*
|
2002-12-23 |
2004-07-15 |
Apalexo Biotechnologie Gmbh |
Reinigung rekombinanter filamentöser bakteriophagen mittels affinitätschromatografie zur erhöhung der immunogenität und wirkung von phagenimpfstoffen
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
DK1575517T3
(da)
|
2002-12-24 |
2012-05-14 |
Rinat Neuroscience Corp |
Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
|
CA2512590A1
(en)
|
2003-01-07 |
2004-07-29 |
Dyax Corporation |
Kunitz domain library
|
US20050079574A1
(en)
*
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1585815A4
(de)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7429472B2
(en)
*
|
2003-01-31 |
2008-09-30 |
Promega Corporation |
Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
|
JP4748685B2
(ja)
|
2003-01-31 |
2011-08-17 |
プロメガ コーポレイション |
タンパク質に対する官能基の共有結合的テザリング
|
EP1592776A4
(de)
*
|
2003-02-01 |
2008-06-04 |
Tanox Inc |
Hochaffine anti-mensch-ige-antikörper
|
CA2516454A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
SI1606409T1
(sl)
*
|
2003-03-19 |
2011-01-31 |
Biogen Idec Inc |
Vezavni protein receptorja Nogo
|
JP2006520806A
(ja)
*
|
2003-03-20 |
2006-09-14 |
ライナット ニューロサイエンス コーポレイション |
タキソール誘導性腸障害を処置する方法
|
US7294701B2
(en)
*
|
2003-04-02 |
2007-11-13 |
Technion Research & Development Foundation Ltd. |
Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
ES2408582T3
(es)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Biblioteca de Fab para la preparación de una mezcla de anticuerpos
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
DE602004019919D1
(de)
|
2003-06-06 |
2009-04-23 |
Genentech Inc |
Modulation der wechselwirkung zwischen hgf-beta-kette und c-met
|
CA2542232A1
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals, Inc. |
Method for treating neurodegenerative disease by inhibiting alpha-synuclein
|
CA2528669A1
(en)
*
|
2003-06-09 |
2005-01-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
CA2530284A1
(en)
|
2003-07-08 |
2005-02-03 |
Genentech, Inc. |
Il-17 a/f heterologous polypeptides and therapeutic uses thereof
|
US20050058658A1
(en)
*
|
2003-07-15 |
2005-03-17 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
|
JP2008500005A
(ja)
*
|
2003-07-15 |
2008-01-10 |
バロス リサーチ インスティテュート |
癌及び感染症の免疫療法のための組成物及び方法
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
US7758859B2
(en)
*
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
EP1668111A4
(de)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
Osteoarthritis-biomarker und verwendungen davon
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
CA2537984A1
(en)
*
|
2003-09-05 |
2005-03-17 |
The Scripps Research Institute |
Detection of cholesterol ozonation products
|
EP1670812A2
(de)
*
|
2003-09-05 |
2006-06-21 |
The Scripps Research Institute |
Produkte der ozonierung von cholesterin zur behandlung und prävention von atherosklerose und/oder herzkreislauferkrankungen
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
WO2005034732A2
(en)
|
2003-10-07 |
2005-04-21 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
|
DK1677735T3
(da)
|
2003-10-17 |
2014-10-27 |
Joslin Diabetes Center Inc |
Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
|
US7329725B1
(en)
*
|
2003-10-29 |
2008-02-12 |
Nastech Pharmaceutical Company Inc. |
Phage displayed Trp cage ligands
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
HUE026260T2
(en)
|
2003-11-21 |
2016-06-28 |
Ucb Biopharma Sprl |
A method for treating multiple sclerosis by inhibiting IL-17 activity
|
CA2548180C
(en)
*
|
2003-12-04 |
2014-02-04 |
Vaccinex, Inc. |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
US20050233960A1
(en)
|
2003-12-11 |
2005-10-20 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
GB0329825D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
WO2005062955A2
(en)
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
PT2177537E
(pt)
|
2004-01-09 |
2011-12-13 |
Pfizer |
Anticorpos contra madcam
|
US20060148680A1
(en)
|
2004-01-14 |
2006-07-06 |
Kieliszewski Marcia J |
Glycoproteins produced in plants and methods of their use
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
WO2005069970A2
(en)
|
2004-01-20 |
2005-08-04 |
Kalobios, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
EP1714151A4
(de)
|
2004-01-21 |
2009-06-10 |
Fujirebio America Inc |
Nachweis von mit mesothelin-/megakaryozyt-potenzierungsfaktor verwandten peptiden in peritonealflüssigkeit zur beurteilung des peritoneums und der peritonealhöhle
|
CA2552043A1
(en)
|
2004-01-21 |
2005-08-04 |
Novo Nordisk A/S |
Transglutaminase mediated conjugation of peptides
|
BRPI0507169A
(pt)
*
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
AU2005209909B8
(en)
*
|
2004-02-03 |
2009-01-15 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
DK1716181T3
(da)
|
2004-02-19 |
2010-03-01 |
Genentech Inc |
CDR-reparerede antistoffer
|
JP5557982B2
(ja)
|
2004-03-01 |
2014-07-23 |
イミューン ディズィーズ インスティテュート インコーポレイテッド |
天然IgM抗体およびその阻害剤
|
WO2005088308A2
(en)
*
|
2004-03-12 |
2005-09-22 |
The Scripps Research Institute |
Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
|
KR20110027823A
(ko)
|
2004-03-24 |
2011-03-16 |
트리패스 이미징, 인코포레이티드 |
자궁경부 질환의 검사 방법 및 조성물
|
EP1786463A4
(de)
*
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
Antikörper gegen nogo-rezeptor
|
EP1740615B1
(de)
|
2004-03-31 |
2014-11-05 |
Genentech, Inc. |
Humanisierte anti-tgf-beta-antikörper
|
TWI367101B
(en)
*
|
2004-04-07 |
2012-07-01 |
Rinat Neuroscience Corp |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
TWI556829B
(zh)
|
2004-04-09 |
2016-11-11 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
WO2005106038A2
(en)
|
2004-04-15 |
2005-11-10 |
University Of Florida Research Foundation, Inc. |
Neural proteins as biomarkers for nervous system injury and other neural disorders
|
WO2005118621A2
(en)
*
|
2004-04-16 |
2005-12-15 |
Genentech, Inc. |
Omi pdz modulators
|
CA2573918A1
(en)
|
2004-04-19 |
2005-11-24 |
Ohio University |
Cross-linkable glycoproteins and methods of making the same
|
CA2562764A1
(en)
|
2004-04-23 |
2005-11-03 |
Richard Kroczek |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
WO2005118647A2
(en)
*
|
2004-05-18 |
2005-12-15 |
Genentech, Inc. |
M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
|
EP1602928A1
(de)
*
|
2004-06-01 |
2005-12-07 |
Universiteit Maastricht |
Verfahren und Kit zur Bestimmung der Bindungsparameter von Bioaffinitätsbindungsreaktionen
|
EP1766014A4
(de)
|
2004-06-03 |
2008-12-10 |
Athlomics Pty Ltd |
Mittel und verfahren zur diagnose von stress
|
WO2005119244A1
(en)
*
|
2004-06-03 |
2005-12-15 |
Phylogica Limited |
Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
|
US7604947B2
(en)
*
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
JP2008503217A
(ja)
*
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
ES2395094T3
(es)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Tratamiento de afecciones que implican la desmielinización
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
JP2008506681A
(ja)
|
2004-07-16 |
2008-03-06 |
ファイザー・プロダクツ・インク |
抗igf−1r抗体を用いる非血液性の悪性腫瘍の併用療法
|
ZA200701183B
(en)
|
2004-07-20 |
2008-05-28 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein, combinations, an their use
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
EP1771573A4
(de)
*
|
2004-07-21 |
2009-02-18 |
Ambrx Inc |
Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
|
US7342093B2
(en)
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
CA2575663C
(en)
*
|
2004-07-30 |
2013-04-23 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
US20070087400A1
(en)
*
|
2004-07-30 |
2007-04-19 |
Aldis Darzins |
Covalent tethering of functional groups to proteins and substrates therefor
|
US7425436B2
(en)
*
|
2004-07-30 |
2008-09-16 |
Promega Corporation |
Covalent tethering of functional groups to proteins and substrates therefor
|
CN101014245A
(zh)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
神经元功能中的taj
|
KR101364276B1
(ko)
*
|
2004-09-03 |
2014-02-20 |
제넨테크, 인크. |
인간화 항-베타7 길항제 및 그의 용도
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
DK1802334T3
(da)
|
2004-10-21 |
2012-10-15 |
Genentech Inc |
Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CA2591587A1
(en)
*
|
2004-12-16 |
2006-06-22 |
Genentech, Inc. |
Methods for treating autoimmune disorders
|
EP1833970A2
(de)
|
2004-12-22 |
2007-09-19 |
Genentech, Inc. |
Verfahren zur herstellung löslicher, mehrere membranen überspannender proteine
|
AU2005319518B2
(en)
*
|
2004-12-22 |
2010-09-09 |
Ambrx, Inc. |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
US7816320B2
(en)
*
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
KR20070090023A
(ko)
*
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
변형 인간 성장 호르몬
|
ATE423140T1
(de)
|
2005-01-05 |
2009-03-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
WO2006074397A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
CN103497993A
(zh)
|
2005-02-07 |
2014-01-08 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
WO2006089133A2
(en)
|
2005-02-15 |
2006-08-24 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
WO2006096565A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
JP5153613B2
(ja)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
抗体のフレームワーク・シャッフル
|
EP3354265A1
(de)
|
2005-03-22 |
2018-08-01 |
President and Fellows of Harvard College |
Behandlung von proteinabbaustörungen
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
JP5122441B2
(ja)
|
2005-04-19 |
2013-01-16 |
シアトル ジェネティックス, インコーポレイテッド |
ヒト化抗cd70結合剤およびその使用
|
US7807159B2
(en)
|
2005-04-25 |
2010-10-05 |
Amgen Fremont Inc. |
Antibodies to myostatin
|
AR054260A1
(es)
*
|
2005-04-26 |
2007-06-13 |
Rinat Neuroscience Corp |
Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
MY148086A
(en)
*
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
EP2500037A3
(de)
|
2005-05-16 |
2012-10-24 |
Abbott Biotechnology Ltd |
Verwendung eines TNF-Hemmers zur Behandlung von erosiver Polyarthritis
|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
US7393919B2
(en)
*
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
ME00261B
(me)
|
2005-05-27 |
2011-02-10 |
Biogen Idec Inc |
Tweak vezujuća antitijela
|
US20100135959A1
(en)
*
|
2005-06-03 |
2010-06-03 |
Ambrx, Inc. |
Human Interferon Molecules and Their Uses
|
CA2610709A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
NZ565044A
(en)
|
2005-06-17 |
2010-05-28 |
Elan Pharma Int Ltd |
Methods of purifying anti A beta antibodies with calcium chloride
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
WO2007005955A2
(en)
|
2005-06-30 |
2007-01-11 |
Centocor, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
UA96922C2
(en)
|
2005-06-30 |
2011-12-26 |
Эббот Леборейториз |
Il-12/p40 binding protein
|
NZ564923A
(en)
|
2005-07-07 |
2012-02-24 |
Athlomics Pty Ltd |
Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
|
EP1904652A2
(de)
*
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
|
BRPI0613387A2
(pt)
|
2005-07-08 |
2011-01-11 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
|
WO2007014169A2
(en)
|
2005-07-22 |
2007-02-01 |
Y's Therapeutics Co, Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
US8187817B2
(en)
|
2005-08-02 |
2012-05-29 |
Xbiotech, Inc. |
Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
|
NZ565631A
(en)
|
2005-08-03 |
2011-01-28 |
Adelaide Res & Innovation Pty |
Polysaccharide synthases
|
EP1995321A2
(de)
|
2005-08-15 |
2008-11-26 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
KR101285904B1
(ko)
|
2005-08-18 |
2013-07-15 |
암브룩스, 인코포레이티드 |
tRNA 조성물 및 이의 용도
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP2500359A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
UY29783A1
(es)
|
2005-09-07 |
2007-04-30 |
Pfizer |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
WO2007031734A1
(en)
*
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A. |
Comb polymers
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
KR101176830B1
(ko)
|
2005-10-17 |
2012-08-27 |
주식회사 아이지세라피 |
신규한 파아지 디스플레이 방법
|
US8239136B2
(en)
|
2005-10-21 |
2012-08-07 |
Genenews Inc. |
Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
|
US8597646B2
(en)
|
2005-10-25 |
2013-12-03 |
The Johns Hopkins University |
Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
|
JP2009513708A
(ja)
|
2005-10-31 |
2009-04-02 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
癌の診断および処置のための組成物および方法
|
EP1945754B1
(de)
*
|
2005-10-31 |
2014-07-23 |
The Regents Of The University Of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
TW201337266A
(zh)
|
2005-11-01 |
2013-09-16 |
Abbott Biotech Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
EA014900B1
(ru)
|
2005-11-07 |
2011-02-28 |
Зе Скрипс Ресеч Инститьют |
Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
|
EP2465870A1
(de)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
|
CA2625540C
(en)
*
|
2005-11-08 |
2017-03-21 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
UA96139C2
(uk)
*
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP2365334A1
(de)
|
2005-11-14 |
2011-09-14 |
MetaMol Theranostics, LLC |
Peptidsequenz, die die Tumorinvasion fördert
|
CA2626120C
(en)
|
2005-11-14 |
2012-12-04 |
Rinat Neuroscience Corp. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
EP2339014B1
(de)
*
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
|
EP1962584A2
(de)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
|
DK1963369T3
(da)
|
2005-11-28 |
2013-06-03 |
Zymogenetics Inc |
Il-21-antagonister
|
DK1954718T3
(en)
|
2005-11-30 |
2014-12-15 |
Abbvie Inc |
Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
|
CN101495869B
(zh)
|
2005-11-30 |
2013-06-19 |
麻省理工学院 |
病原体检测方法
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
EP2543384A3
(de)
|
2005-12-02 |
2013-04-10 |
Biogen Idec MA Inc. |
Behandlung von Zuständen mithilfe von Demyelinisation
|
AU2006338198B2
(en)
|
2005-12-02 |
2012-04-26 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
US20070237764A1
(en)
*
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
ZA200804594B
(en)
|
2005-12-09 |
2010-08-25 |
Ucb Pharma Sa |
Antibody molecules having specificity for human IL-6
|
CA2631491C
(en)
*
|
2005-12-14 |
2015-02-24 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
CN103396485B
(zh)
|
2005-12-15 |
2016-08-10 |
健泰科生物技术公司 |
靶向多聚泛蛋白的方法和组合物
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
SI2548577T1
(sl)
|
2005-12-29 |
2017-05-31 |
Janssen Biotech, Inc. |
Človeška protitelesa proti il-23, sestavki, postopki in uporabe
|
CA2638785C
(en)
|
2006-01-05 |
2017-02-21 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
ES2709672T3
(es)
|
2006-01-12 |
2019-04-17 |
Alexion Pharma Inc |
Anticuerpos para OX-2/CD200 y usos de los mismos
|
US20070212721A1
(en)
|
2006-01-27 |
2007-09-13 |
Tripath Imaging, Inc. |
Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
|
EP2526968A3
(de)
|
2006-01-27 |
2013-05-22 |
Biogen Idec MA Inc. |
Nogo-Rezeptorantagonisten
|
WO2007090126A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
WO2007087673A1
(en)
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
JP5441416B2
(ja)
|
2006-02-14 |
2014-03-12 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二官能性ヒストンデアセチラーゼインヒビター
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
CA2638912A1
(en)
|
2006-02-20 |
2007-08-30 |
Phylogica Limited |
Method of constructing and screening libraries of peptide structures
|
US20070243192A1
(en)
*
|
2006-02-21 |
2007-10-18 |
Regents Of The University Of Michigan |
Growth hormone receptor antagonist cancer treatment
|
US20080019961A1
(en)
*
|
2006-02-21 |
2008-01-24 |
Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
WO2007100711A2
(en)
*
|
2006-02-24 |
2007-09-07 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
WO2007103469A2
(en)
|
2006-03-06 |
2007-09-13 |
Aeres Biomedical Ltd. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
EP2007428A2
(de)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
|
CN101454025B
(zh)
|
2006-04-05 |
2014-01-01 |
艾伯维生物技术有限公司 |
抗体纯化
|
EP2666479A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
US7695928B2
(en)
|
2006-04-10 |
2010-04-13 |
Genentech, Inc. |
Disheveled PDZ modulators
|
EP2666472A3
(de)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
|
WO2008036437A2
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
JP5497431B2
(ja)
|
2006-05-03 |
2014-05-21 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US20070292936A1
(en)
*
|
2006-05-09 |
2007-12-20 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
US20090142259A1
(en)
*
|
2006-05-12 |
2009-06-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
KR20090027227A
(ko)
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-dll4 항체 및 이의 사용 방법
|
SG172684A1
(en)
|
2006-06-07 |
2011-07-28 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
DK2029173T3
(en)
|
2006-06-26 |
2016-11-07 |
Macrogenics Inc |
FC-RIIB-specific antibodies and methods of use thereof
|
DE102006030028A1
(de)
*
|
2006-06-29 |
2008-02-14 |
Forschungszentrum Jülich GmbH |
Verfahren zum Auffinden von spezifisch an einen Köder bindende Moleküle, sowie spezifisch an einen Köder bindende Moleküle und deren Verwendung
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
NZ572765A
(en)
|
2006-06-30 |
2012-08-31 |
Abbott Biotech Ltd |
Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
NZ574140A
(en)
*
|
2006-07-05 |
2012-02-24 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
WO2008010101A2
(en)
*
|
2006-07-18 |
2008-01-24 |
Sanofi-Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
LT2511301T
(lt)
|
2006-08-04 |
2018-04-10 |
Medimmune Limited |
Žmogaus antikūnas prieš erbb2
|
EP2520935A3
(de)
|
2006-08-09 |
2013-02-13 |
Homestead Clinical Corporation |
Organspezifische Proteine und Verfahren zu deren Verwendung
|
AU2007290570C1
(en)
|
2006-08-28 |
2013-08-15 |
Kyowa Kirin Co., Ltd. |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
EP2089722B1
(de)
|
2006-09-07 |
2017-11-08 |
Otago Innovation Limited |
Biomarker zur Früherkennung akuter Herzstörungen
|
EP2615108B1
(de)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
|
MX2009002460A
(es)
*
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Arnt supresor hibrido para celulas de vertebrados.
|
ES2817756T3
(es)
|
2006-09-08 |
2021-04-08 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleuquina-13
|
US8420792B2
(en)
*
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
US8063012B2
(en)
*
|
2006-09-19 |
2011-11-22 |
Phylogica Limited |
Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
|
AU2007302448C1
(en)
|
2006-09-26 |
2019-02-14 |
Genmab A/S |
Combination treatment of CD38-expressing tumors
|
DK2066694T3
(en)
|
2006-09-29 |
2016-02-08 |
Oncomed Pharm Inc |
Compositions and Methods for Diagnosing and Treating Cancer
|
WO2008045563A2
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
RU2486201C2
(ru)
*
|
2006-10-12 |
2013-06-27 |
Дженентек, Инк. |
Антитела к лимфотоксину-альфа
|
EP2407548A1
(de)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP1914242A1
(de)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
US20080096193A1
(en)
*
|
2006-10-24 |
2008-04-24 |
Charles Robert Bupp |
Methods and compositions for detecting polynucleotides
|
LT2845866T
(lt)
|
2006-10-27 |
2017-07-10 |
Genentech, Inc. |
Antikūnai ir imunokonjugatai bei jų panaudojimas
|
JP5680302B2
(ja)
|
2006-10-30 |
2015-03-04 |
プロメガ コーポレイションPromega Corporation |
キネティクス及び機能発現が高められた突然変異形ヒドロラーゼ・タンパク質
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
CN101641106A
(zh)
|
2006-11-15 |
2010-02-03 |
功能遗传学股份有限公司 |
抗-tsg101抗体及其用于治疗病毒感染的用途
|
WO2008064306A2
(en)
*
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
US7488807B2
(en)
|
2006-11-22 |
2009-02-10 |
3M Innovative Properties Company |
Antibody with protein A selectivity
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008067547A2
(en)
|
2006-11-30 |
2008-06-05 |
Research Development Foundation |
Improved immunoglobulin libraries
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
JP5646174B2
(ja)
|
2006-12-05 |
2014-12-24 |
デコード・ジェネティクス・イーエイチエフ |
心臓不整脈のリスクマネージメント用の遺伝マーカー
|
EP2687232A1
(de)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Verfahren zur Behandlung von systemischem Lupus erythematodes
|
PL2101807T3
(pl)
|
2006-12-19 |
2016-11-30 |
|
Antagoniści specyficzni względem VEGF dla terapii adiuwantem i neoadiuwantem i leczenie wczesnych stadiów guzów
|
CN103405768A
(zh)
|
2006-12-20 |
2013-11-27 |
爱克索马技术有限公司 |
用于治疗IL-1β相关疾病的方法
|
TW200833711A
(en)
*
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
EP2097448A4
(de)
|
2006-12-22 |
2010-07-21 |
Univ Utah Res Found |
Verfahren für den nachweis von augenerkrankungen und leiden sowie ihre behandlung
|
NZ596237A
(en)
|
2006-12-27 |
2012-07-27 |
Dana Farber Cancer Inst Inc |
Compositions and methods for the treatment of infections and tumors
|
EP2114443A4
(de)
|
2006-12-29 |
2011-08-10 |
Abbott Lab |
Doppelt spezifische il-1a/il-1b-antikörper
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
ES2673153T3
(es)
|
2007-01-09 |
2018-06-20 |
Biogen Ma Inc. |
Anticuerpos Sp35 y usos de los mismos
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
US8148147B2
(en)
*
|
2007-01-24 |
2012-04-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
US8664364B2
(en)
|
2007-01-24 |
2014-03-04 |
Carnegie Mellon University |
Optical biosensors
|
CN102317470A
(zh)
|
2007-02-07 |
2012-01-11 |
解码遗传学私营有限责任公司 |
促进前列腺癌风险的遗传性变型
|
BRPI0806403A2
(pt)
|
2007-02-09 |
2011-09-06 |
Genentech Inc |
anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
|
WO2008101184A2
(en)
*
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
KR101571523B1
(ko)
|
2007-02-21 |
2015-11-24 |
디코드 제네틱스 이에이치에프 |
심혈관 질환과 연관된 유전적 감수성 변이
|
KR101508397B1
(ko)
|
2007-02-22 |
2015-04-08 |
제넨테크, 인크. |
염증성 장 질환의 검출 방법
|
WO2008103702A2
(en)
*
|
2007-02-23 |
2008-08-28 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
EP3118221B1
(de)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteine
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2121919B1
(de)
|
2007-03-22 |
2012-02-08 |
Heptares Therapeutics Limited |
Mutante g-protein-gekoppelte rezeptoren und selektionsverfahren dafür
|
TWI417299B
(zh)
|
2007-03-22 |
2013-12-01 |
Biogen Idec Inc |
包括抗體、抗體衍生物及抗體片段之專一性地結合至cd154之結合蛋白及其用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP2142565A4
(de)
|
2007-03-29 |
2010-03-31 |
Abbott Lab |
Kristalline antikörper gegen humanes il-12
|
ES2385114T3
(es)
|
2007-03-30 |
2012-07-18 |
Ambrx, Inc. |
Polipéptidos de FGF-21 modificados y sus usos
|
US20100209434A1
(en)
|
2007-03-30 |
2010-08-19 |
Medimmune, Llc |
Antibody formulation
|
SG182985A1
(en)
|
2007-04-02 |
2012-08-30 |
Amgen Fremont Inc |
Anti-ige antibodies
|
US20100291562A1
(en)
*
|
2007-04-04 |
2010-11-18 |
Michael Adler |
Method for the detection of an analyte in biological matrix
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
KR20150067772A
(ko)
|
2007-04-13 |
2015-06-18 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
변형 제vii 인자 폴리펩타이드 및 이의 용도
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
WO2008136694A1
(en)
|
2007-05-04 |
2008-11-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
NO3072525T3
(de)
|
2007-05-14 |
2018-06-30 |
|
|
CA2687556A1
(en)
|
2007-05-17 |
2008-11-27 |
Genentech, Inc. |
Crystal structures of neuropilin fragments and neuropilin-antibody complexes
|
NZ581858A
(en)
|
2007-05-25 |
2012-07-27 |
Decode Genetics Ehf |
Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
|
US7906149B2
(en)
*
|
2007-05-25 |
2011-03-15 |
Boval Company, L.P. |
Method for treating allergic dermatitis
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
EP2171451A4
(de)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
Verfahren zur behandlung juveniler idiopathischer arthritis
|
CA2958672A1
(en)
|
2007-06-15 |
2008-12-18 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Treatment of tumors using specific anti-l1 antibody
|
WO2008154700A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Phylogica Limited |
Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
|
AU2009258063B2
(en)
|
2007-06-21 |
2014-09-25 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
EP3424951A1
(de)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
DK2158220T3
(en)
|
2007-06-26 |
2017-07-10 |
F-Star Biotechnologische Forschungs- Und Entw M B H |
Display of binders
|
US8158758B2
(en)
|
2007-07-02 |
2012-04-17 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
EP2641618A3
(de)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
|
PL2474557T3
(pl)
|
2007-07-16 |
2015-02-27 |
Genentech Inc |
Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
|
JP2010534664A
(ja)
|
2007-07-23 |
2010-11-11 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
Il−17拮抗薬を用いた線維症関連疾患治療の方法及び組成物
|
MX2010000979A
(es)
*
|
2007-07-25 |
2010-03-26 |
Alexion Pharma Inc |
Metodos y composiciones para tratar enfermedad autoinmune.
|
WO2009020477A1
(en)
*
|
2007-08-06 |
2009-02-12 |
Yale University |
Modified miniature proteins
|
AU2008290539B2
(en)
|
2007-08-21 |
2013-07-25 |
Morphosys Ag |
Improved methods for the formation of disulphide bonds
|
EP2570431A3
(de)
*
|
2007-08-30 |
2013-05-01 |
CureDM Group Holdings, LLC |
Zusammensetzungen und Verfahren zur Anwendung von Proinselzellpeptiden und Analoga Davon
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
EP2193146B1
(de)
|
2007-09-14 |
2016-05-25 |
Adimab, LLC |
Synthetische antikörperbibliotheken mit rationalem design und ihre verwendung
|
EP2535349A1
(de)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Antikörperfusionen mit Doppelspezifität
|
KR101922788B1
(ko)
|
2007-09-26 |
2018-11-27 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
AU2008307145B2
(en)
*
|
2007-10-04 |
2014-07-10 |
Bionomics Limited |
Markers of endothelial cells and uses thereof
|
EP2219452B1
(de)
|
2007-11-05 |
2015-10-14 |
MedImmune, LLC |
Verfahren zur behandlung von skleroderm
|
PT2514436T
(pt)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 para utilização no tratamento de distúrbios microbianos
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
NZ603812A
(en)
*
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
EP2225275A4
(de)
*
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
Proteinformulierung
|
US8697360B2
(en)
|
2007-11-30 |
2014-04-15 |
Decode Genetics Ehf. |
Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
US8426153B2
(en)
|
2007-12-03 |
2013-04-23 |
Carnegie Mellon University |
Linked peptides fluorogenic biosensors
|
GB0724051D0
(en)
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
CN102216329A
(zh)
|
2007-12-17 |
2011-10-12 |
辉瑞有限公司 |
间质性膀胱炎的治疗
|
ES2550757T3
(es)
|
2007-12-18 |
2015-11-12 |
Bioalliance C.V. |
Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD43 y ACE expresados en células cancerosas y métodos de uso de los mismos
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
DK2391650T3
(en)
|
2007-12-20 |
2015-01-12 |
Xoma Us Llc |
Methods of treating gout
|
EP2237792B1
(de)
|
2007-12-26 |
2017-05-24 |
Vaccinex, Inc. |
Anti-c35-antikörper-kombinationstherapien und verfahren
|
JP5730020B2
(ja)
|
2007-12-28 |
2015-06-03 |
ネオトープ バイオサイエンシーズ リミテッド |
アミロイドーシスの処置および予防
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
CA2711771C
(en)
|
2008-01-11 |
2017-01-24 |
Gene Techno Science Co., Ltd. |
Humanized anti-.alpha.9 integrin antibodies and the uses thereof
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
TWI640535B
(zh)
|
2008-01-31 |
2018-11-11 |
建南德克公司 |
抗-cd79b抗體及免疫共軛物及使用方法
|
BR122020023189B1
(pt)
|
2008-02-08 |
2022-02-01 |
Astrazeneca Ab |
Uso de uma composição farmacêutica compreendendo um anticorpo específico para ifnar1
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
GB0802474D0
(en)
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
CA2714521A1
(en)
|
2008-02-14 |
2009-08-20 |
Decode Genetics Ehf |
Susceptibility variants for lung cancer
|
US8697374B2
(en)
|
2008-02-28 |
2014-04-15 |
3M Innovative Properties Company |
Antibodies to Clostridium difficile spores and uses thereof
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
WO2009109572A2
(en)
*
|
2008-03-03 |
2009-09-11 |
Ablynx Nv |
Monovalent phage display of single variable domains
|
JP5537441B2
(ja)
|
2008-03-04 |
2014-07-02 |
ファイザー・リミテッド |
慢性疼痛を治療する方法
|
EP2265288B1
(de)
|
2008-03-04 |
2016-05-11 |
Labrys Biologics Inc. |
Verfahren zur behandlung von entzündlichen schmerzen
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
AU2009224113B2
(en)
|
2008-03-12 |
2013-02-21 |
Otago Innovation Limited |
Biomarkers
|
JP2011516038A
(ja)
|
2008-03-12 |
2011-05-26 |
オタゴ イノベーション リミテッド |
バイオマーカー
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
EP2274333A4
(de)
|
2008-03-18 |
2011-06-15 |
Abbott Lab |
Verfahren zur behandlung von psoriasis
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
NZ601815A
(en)
*
|
2008-03-31 |
2014-10-31 |
Genentech Inc |
Compositions and methods for treating and diagnosing asthma
|
CA2724666A1
(en)
|
2008-04-01 |
2009-10-08 |
Decode Genetics Ehf |
Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
|
CA2720368C
(en)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
CA2720699C
(en)
|
2008-04-11 |
2018-01-02 |
Seattle Genetics, Inc. |
Detection and treatment of pancreatic, ovarian and other cancers using antibodies that specifically bind to denatured cd70
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
CA2722409C
(en)
|
2008-04-24 |
2017-12-12 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
AU2009238897B2
(en)
|
2008-04-24 |
2015-03-19 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
EP3348573B1
(de)
|
2008-04-25 |
2020-04-22 |
Dyax Corp. |
Methode zur herstellung von antikörper gegen fcrn
|
NZ588554A
(en)
|
2008-04-29 |
2013-03-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
CL2009001083A1
(es)
|
2008-05-06 |
2011-01-07 |
Genentech Inc |
Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune.
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
BRPI0908665A2
(pt)
*
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
MX2010013236A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
CN102112495A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP2282770B1
(de)
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2010004591A2
(en)
|
2008-07-07 |
2010-01-14 |
Decode Genetics Ehf |
Genetic variants for breast cancer risk assessment
|
ES2535614T3
(es)
|
2008-07-08 |
2015-05-13 |
Oncomed Pharmaceuticals, Inc. |
Agentes de unión a Notch y antagonistas y métodos de uso de los mismos
|
RU2011104348A
(ru)
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
EP2810654A1
(de)
|
2008-07-08 |
2014-12-10 |
AbbVie Inc. |
Prostaglandin-E2 bindende Proteine und ihre Verwendung
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
UA103774C2
(uk)
|
2008-07-23 |
2013-11-25 |
Амбркс, Інк. |
Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
|
AU2009274549B2
(en)
|
2008-07-23 |
2014-05-01 |
Dana-Farber Cancer Institute, Inc. |
Deacetylase inhibitors and uses thereof
|
US9182406B2
(en)
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
JP5977945B2
(ja)
|
2008-08-06 |
2016-08-24 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
長期のインビボ有効性を有するコンジュゲートタンパク質
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
AU2009281713B9
(en)
|
2008-08-14 |
2014-05-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-IL-12/IL-23 antibodies
|
EP2342336B1
(de)
|
2008-09-05 |
2016-12-14 |
President and Fellows of Harvard College |
Kontinuierliche gerichtete evolution von proteinen und nukleinsäuren
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
WO2010033229A2
(en)
*
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of molecules and displayed molecules and collections
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
CN102224254A
(zh)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4及其用途
|
WO2010036964A2
(en)
|
2008-09-26 |
2010-04-01 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
MX2011003195A
(es)
|
2008-09-26 |
2011-08-12 |
Dana Farber Cancer Inst Inc |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
MX2011003183A
(es)
|
2008-09-26 |
2011-04-21 |
Oncomed Pharm Inc |
Agentes que se unen a receptor encrespado y usos de los mismos.
|
DK2337846T3
(en)
|
2008-09-26 |
2018-03-12 |
Ambrx Inc |
NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES
|
EP2364359A2
(de)
|
2008-09-26 |
2011-09-14 |
Wyeth LLC |
Kompatible display-vektorsysteme
|
ES2659875T3
(es)
|
2008-10-10 |
2018-03-19 |
Children's Medical Center Corporation |
Vacuna de trímero de Env VIH-1 bioquímicamente estabilizado
|
JP2012505900A
(ja)
|
2008-10-14 |
2012-03-08 |
ダイアクス コーポレーション |
全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用
|
WO2010047515A2
(ko)
|
2008-10-20 |
2010-04-29 |
광주과학기술원 |
바이포달 펩타이드 바인더
|
CA2932207A1
(en)
|
2008-10-20 |
2010-12-09 |
Abbvie Inc. |
Isolation and purification of antibodies using protein a affinity chromatography
|
CA2741523C
(en)
|
2008-10-24 |
2022-06-21 |
Jonathan S. Towner |
Human ebola virus species and compositions and methods thereof
|
AU2009333791B2
(en)
|
2008-10-29 |
2013-04-04 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
EP2346904B1
(de)
|
2008-10-29 |
2017-04-12 |
China Synthetic Rubber Corporation |
Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
|
CN102307896B
(zh)
|
2008-10-31 |
2016-10-12 |
森托科尔奥索生物科技公司 |
基于iii型纤连蛋白结构域的支架组合物、方法及用途
|
US9403904B2
(en)
|
2008-11-07 |
2016-08-02 |
Fabrus, Inc. |
Anti-DLL4 antibodies and uses thereof
|
EP3101031A1
(de)
|
2008-11-10 |
2016-12-07 |
Alexion Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von komplementassoziierten erkrankungen
|
KR20110093893A
(ko)
|
2008-11-11 |
2011-08-18 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
항-cxcr1 조성물 및 방법
|
ES2719496T3
(es)
|
2008-11-12 |
2019-07-10 |
Medimmune Llc |
Formulación de anticuerpo
|
EP2189539B2
(de)
|
2008-11-21 |
2018-06-13 |
Chimera Biotec GmbH |
Konjugatkomplexe zum Analytnachweis
|
DK2752189T3
(en)
|
2008-11-22 |
2017-01-16 |
Hoffmann La Roche |
APPLICATION OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
|
JP2012509941A
(ja)
|
2008-11-26 |
2012-04-26 |
ファイブ・プライム・セラピューティクス,インコーポレイテッド |
Serpine2によるコラーゲンおよび平滑筋アクチンの発現を調節するための組成物および方法
|
DK2370593T3
(en)
|
2008-11-28 |
2016-07-04 |
Univ Emory |
A method for determining the effect of PD-1 Antagonists
|
AU2009322236B2
(en)
*
|
2008-12-04 |
2013-11-07 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CN104479018B
(zh)
|
2008-12-09 |
2018-09-21 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
KR101596539B1
(ko)
|
2008-12-23 |
2016-02-22 |
제넨테크, 인크. |
암 환자에서의 진단 목적용 방법 및 조성물
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010085510A1
(en)
|
2009-01-20 |
2010-07-29 |
Zadeh Homayoun H |
Antibody mediated osseous regeneration
|
EP2389394A2
(de)
|
2009-01-21 |
2011-11-30 |
Oxford Biotherapeutics Ltd. |
Pta089-protein
|
EP2389389B1
(de)
|
2009-01-22 |
2015-04-15 |
Novo Nordisk Health Care AG |
Stabile Wachstumshormonverbindungen
|
EP2391748A4
(de)
*
|
2009-01-28 |
2012-08-01 |
Antigen Express Inc |
Li-key-hybridpeptide zur modulation der immunreaktion auf influenza
|
US8383778B2
(en)
|
2009-01-29 |
2013-02-26 |
Abbvie Inc. |
IL-1 binding proteins
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(de)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
|
EP2396011B1
(de)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
|
SG173620A1
(en)
|
2009-02-17 |
2011-09-29 |
Ucb Pharma Sa |
Antibody molecules having specificity for human ox40
|
US9249306B2
(en)
|
2009-02-18 |
2016-02-02 |
Carnegie Mellon University |
Quenched dendrimeric dyes for florescence detection
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
RU2011140335A
(ru)
|
2009-03-05 |
2013-04-10 |
Эбботт Лэборетриз |
Связывающие il-17 белки
|
US20100227335A1
(en)
|
2009-03-05 |
2010-09-09 |
Becton, Dickinson And Company |
Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
EP2403875A1
(de)
|
2009-03-06 |
2012-01-11 |
Tripath Imaging, Inc. |
Monoklonale glycodelin-antikörper und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
US8735552B2
(en)
|
2009-03-10 |
2014-05-27 |
Gene Techno Science Co., Ltd. |
Generation, expression and characterization of the humanized K33N monoclonal antibody
|
GB0904214D0
(en)
*
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
BRPI1006270B1
(pt)
|
2009-03-25 |
2022-08-16 |
Genentech, Inc |
Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1
|
HRP20221471T1
(hr)
|
2009-03-25 |
2023-02-03 |
Genentech, Inc. |
Protutijela anti-fgfr3 i postupci za njihovu uporabu
|
EP2414399A1
(de)
|
2009-04-01 |
2012-02-08 |
F. Hoffmann-La Roche AG |
Anti-fcrh5-antikörper und immunkonjugate und anwendungsverfahren
|
DK2414543T3
(en)
|
2009-04-03 |
2017-01-23 |
Decode Genetics Ehf |
Genetic markers for risk management of atrial fibrillation and stroke
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
JP6141638B2
(ja)
|
2009-04-20 |
2017-06-07 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
カドヘリン−17に特異的な抗体
|
ES2708124T3
(es)
|
2009-04-27 |
2019-04-08 |
Oncomed Pharm Inc |
Procedimiento para preparar moléculas heteromultiméricas
|
WO2010126972A1
(en)
|
2009-04-29 |
2010-11-04 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Erg monoclonal antibodies
|
JP5677411B2
(ja)
|
2009-04-29 |
2015-02-25 |
アッヴィ バイオテクノロジー リミテッド |
自動注入機器
|
BRPI1011195B1
(pt)
*
|
2009-05-20 |
2020-10-13 |
Novimmune S.A |
métodos para produzir uma coleção de ácidos nucleicos
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
WO2010141630A1
(en)
|
2009-06-03 |
2010-12-09 |
University Of Southern California |
Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
|
CN102596221B
(zh)
|
2009-06-10 |
2019-06-04 |
纽约大学 |
病理tau蛋白的免疫靶向
|
EP2261242A1
(de)
|
2009-06-10 |
2010-12-15 |
Universite Catholique De Louvain |
Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
EP2272979A1
(de)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
|
CN102481380A
(zh)
|
2009-07-09 |
2012-05-30 |
霍夫曼-拉罗奇有限公司 |
体内肿瘤血管系统成像
|
EP2451977A4
(de)
|
2009-07-10 |
2013-01-02 |
Decode Genetics Ehf |
Genetische marker für das risiko von diabetes mellitus
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
CN102596220A
(zh)
|
2009-07-31 |
2012-07-18 |
韦恩州立大学 |
单磷酸化的脂质a衍生物
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
US9259476B2
(en)
|
2009-07-31 |
2016-02-16 |
Wayne State University |
Monophosphorylated lipid A derivatives
|
EP2461831B1
(de)
|
2009-08-06 |
2018-11-21 |
Novo Nordisk Health Care AG |
Wachstumshormone mit verlängerter in-vivo-wirksamkeit
|
RU2017138926A
(ru)
|
2009-08-11 |
2019-02-11 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
US8716344B2
(en)
|
2009-08-11 |
2014-05-06 |
President And Fellows Of Harvard College |
Class- and isoform-specific HDAC inhibitors and uses thereof
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
AR077848A1
(es)
|
2009-08-15 |
2011-09-28 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
WO2011024113A1
(en)
|
2009-08-28 |
2011-03-03 |
Rinat Neuroscience Corporation |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
AU2010286518C1
(en)
|
2009-08-29 |
2015-08-27 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2475682B1
(de)
|
2009-09-10 |
2018-01-31 |
UCB Biopharma SPRL |
Polyvalente antikörper
|
CN102630168A
(zh)
|
2009-09-14 |
2012-08-08 |
雅培制药有限公司 |
用于治疗银屑病的方法
|
AU2010291902A1
(en)
*
|
2009-09-14 |
2012-04-05 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
CA2772670A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
US20120244170A1
(en)
|
2009-09-22 |
2012-09-27 |
Rafal Ciosk |
Treating cancer by modulating mex-3
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8926976B2
(en)
*
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9598692B2
(en)
|
2009-09-25 |
2017-03-21 |
University Of Oslo |
Multivalent phage display systems and methods
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
JP5885664B2
(ja)
|
2009-09-25 |
2016-03-15 |
ゾーマ テクノロジー リミテッド |
スクリーニング法
|
CN102869775A
(zh)
|
2009-09-30 |
2013-01-09 |
哈佛大学校长及研究员协会 |
通过调节自噬抑制基因产物调节自噬的方法
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
EP2488658A4
(de)
|
2009-10-15 |
2013-06-19 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
EP3072526B1
(de)
|
2009-10-16 |
2018-09-26 |
Oncomed Pharmaceuticals, Inc. |
Therapeutische kombination und verwendung mit dll4-antagonistische antikörper und mittel gegen bluthochdruck
|
ES2813398T3
(es)
|
2009-10-20 |
2021-03-23 |
Abbvie Inc |
Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック, インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
EP2496605A1
(de)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 als therapeutisches und diagnostisches ziel
|
EP2496243A2
(de)
|
2009-11-04 |
2012-09-12 |
Erasmus University Medical Center Rotterdam |
Neuartige verbindungen zur modulierung der gefässneubildung und behandlungsverfahren mit diesen verbindungen
|
CA2780143A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
EP2499491B1
(de)
|
2009-11-11 |
2015-04-01 |
Gentian AS |
Immunassay zur untersuchung von assoziierten analyten unterschiedlichen ursprungs
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
RU2015132142A
(ru)
|
2009-11-30 |
2015-12-20 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US9175075B2
(en)
|
2009-12-08 |
2015-11-03 |
AbbVie Deutschland GmbH & Co. KG |
Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
|
SI2510011T1
(sl)
|
2009-12-09 |
2014-12-31 |
Institut National De La Sante Et De La Recherche Medicale |
Monoklonska protitelesa, ki veĹľejo B7H6 in njihova uporaba
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
EP2513148B1
(de)
*
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2-antikörper und ihre verwendung
|
AU2010339770B2
(en)
|
2009-12-21 |
2015-02-12 |
Genentech, Inc. |
Antibody formulation
|
CN102666578A
(zh)
|
2009-12-21 |
2012-09-12 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
TW201125583A
(en)
*
|
2009-12-23 |
2011-08-01 |
Bioalliance Cv |
Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
|
PT3459564T
(pt)
|
2010-01-06 |
2022-01-31 |
Takeda Pharmaceuticals Co |
Proteínas de ligação à calicreína plasmática
|
NZ601111A
(en)
|
2010-01-11 |
2014-07-25 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
AU2011205316B2
(en)
|
2010-01-13 |
2015-05-28 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
PL2525834T3
(pl)
|
2010-01-22 |
2020-10-19 |
Novo Nordisk Health Care Ag |
Hormony wzrostu o przedłużonej skuteczności in-vivo
|
EP2526424A2
(de)
|
2010-01-22 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, prävention und therapie von stoffwechselerkrankungen
|
RU2012134974A
(ru)
|
2010-01-22 |
2014-02-27 |
Ново Нордиск Хелс Кеа Аг |
Стабилизированное соединение гормона роста
|
EP2531613A2
(de)
|
2010-02-02 |
2012-12-12 |
Abbott Biotechnology Ltd. |
Verfahren und zusammensetzungen zur prognose des ansprechens auf eine behandlung mit einem tnf-alpha-hemmer
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
JP5841072B2
(ja)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
Cd20抗体およびその使用
|
EP3178846B1
(de)
|
2010-02-17 |
2018-08-22 |
Cedars-Sinai Medical Center |
Neuartige phosphorylierung von kardialem troponin i als ein monitor einer kardialen verletzung
|
SG183333A1
(en)
|
2010-02-18 |
2012-09-27 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
CA2787657A1
(en)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2539367A2
(de)
|
2010-02-23 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenese-therapie für die behandlung von ovarialkarzinom
|
SG10201501342UA
(en)
|
2010-02-24 |
2015-04-29 |
Immunogen Inc |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
AR080291A1
(es)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas anti receptor de il-7 y procedimientos
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
MX2012010481A
(es)
|
2010-03-11 |
2012-10-09 |
Rinat Neuroscience Corp |
Anticuerpos con union de antigenos dependiente del ph.
|
CN102971012B
(zh)
|
2010-03-12 |
2016-05-04 |
伊缪诺金公司 |
Cd37结合分子及其免疫缀合物
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
CA2793424A1
(en)
*
|
2010-03-18 |
2011-09-22 |
Cornell University |
Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
|
US10706955B2
(en)
|
2010-03-23 |
2020-07-07 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
EP2550295A1
(de)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Antikörper gegen lrp6
|
EP3187585A1
(de)
|
2010-03-25 |
2017-07-05 |
Oregon Health&Science University |
Cmv-glycoproteine und rekombinante vektoren
|
TR201903279T4
(tr)
|
2010-03-25 |
2019-03-21 |
Ucb Biopharma Sprl |
Disülfür stabilize edilmiş DVD-IG molekülleri.
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
MX347515B
(es)
|
2010-04-01 |
2017-04-28 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen al receptor encrespado y usos de los mismos.
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
BR112012027900A2
(pt)
|
2010-04-30 |
2020-05-12 |
Alexion Pharmaceuticals, Inc. |
Anticorpos anti-c5a e métodos para usar os anticorpos
|
CA2793544A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ES2606017T3
(es)
|
2010-05-03 |
2017-03-17 |
University Of Rochester |
Inmunización pasiva anti-glucosaminidasa para infecciones por Staphylococcus aureus
|
DK2571532T3
(en)
|
2010-05-14 |
2017-08-28 |
Abbvie Inc |
IL-1 BINDING PROTEINS
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
US9995679B2
(en)
|
2010-05-25 |
2018-06-12 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
CA2795972A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
WO2011153477A2
(en)
|
2010-06-03 |
2011-12-08 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
US9499813B2
(en)
|
2010-06-10 |
2016-11-22 |
President And Fellows Of Harvard College |
Systems and methods for amplification and phage display
|
EP2580239A1
(de)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
|
MX2012014838A
(es)
|
2010-06-16 |
2013-02-07 |
Abbvie Inc |
Comparacion de las muestras de proteina.
|
MX336001B
(es)
|
2010-06-18 |
2016-01-07 |
Genentech Inc |
Anticuerpos anti-axl y metodos de uso.
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
KR101896124B1
(ko)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법
|
AU2011274528B2
(en)
|
2010-07-09 |
2015-04-23 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
US9354228B2
(en)
|
2010-07-16 |
2016-05-31 |
Adimab, Llc |
Antibody libraries
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
EP2596010B1
(de)
|
2010-07-19 |
2017-04-12 |
Otago Innovation Limited |
Signalbiomarker
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US20130143815A1
(en)
|
2010-07-22 |
2013-06-06 |
Novo Nordisk Health Care Ag |
Growth hormone conjugates
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
DK2601609T3
(en)
|
2010-08-02 |
2017-06-06 |
Population Bio Inc |
COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
|
JP2013541501A
(ja)
|
2010-08-03 |
2013-11-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
慢性リンパ性白血病(cll)のバイオマーカー
|
EP3252072A3
(de)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne und verwendungen davon
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
NZ703653A
(en)
|
2010-08-13 |
2016-09-30 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
KR101653030B1
(ko)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
항-테나신-c a2 항체 및 이의 사용 방법
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
KR101963460B1
(ko)
|
2010-08-17 |
2019-03-28 |
암브룩스, 인코포레이티드 |
변형된 릴랙신 폴리펩타이드 및 그것의 용도
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
EP2606362B1
(de)
|
2010-08-19 |
2015-09-30 |
Roche Diagniostics GmbH |
Assay zur messung der antikörperbindung an einen therapeutischen, monoklonalen antikörper
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012027723A1
(en)
|
2010-08-27 |
2012-03-01 |
Stem Centrx, Inc |
Notum protein modulators and methods of use
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
MX2013003182A
(es)
|
2010-09-20 |
2013-04-24 |
Abbvie Inc |
Purificacion de anticuerpos por cromatografia de lecho movil simulada.
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2446898A1
(de)
|
2010-09-30 |
2012-05-02 |
Laboratorios Del. Dr. Esteve, S.A. |
Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
|
WO2012044921A1
(en)
|
2010-10-01 |
2012-04-05 |
St. Jude Children's Research Hospital |
Methods and compositions for typing molecular subgroups of medulloblastoma
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
AU2011320314B2
(en)
|
2010-10-29 |
2015-08-06 |
Immunogen, Inc. |
Novel EGFR-binding molecules and immunoconjugates thereof
|
AU2011320318B9
(en)
|
2010-10-29 |
2015-11-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
PE20140238A1
(es)
|
2010-11-10 |
2014-03-07 |
Genentech Inc |
Metodos y composiciones para inmunoterapia para enfermedad neural
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
EP2640831A1
(de)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
|
US9072766B2
(en)
|
2010-11-18 |
2015-07-07 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
US9783601B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
NZ611428A
(en)
|
2010-12-08 |
2015-07-31 |
Stemcentrx Inc |
Novel modulators and methods of use
|
MY188365A
(en)
|
2010-12-16 |
2021-12-06 |
Genentech Inc |
Diagnosis and treatments relating to th2 inhibition
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
US9029502B2
(en)
|
2010-12-20 |
2015-05-12 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
EP2655417A2
(de)
|
2010-12-21 |
2013-10-30 |
AbbVie Inc. |
Il-1 alpha- und -beta-bispezifische immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
CA2824279A1
(en)
|
2010-12-22 |
2012-06-28 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life
|
CA2825370A1
(en)
|
2010-12-22 |
2012-06-28 |
President And Fellows Of Harvard College |
Continuous directed evolution
|
KR20130118925A
(ko)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
항-pcsk9 항체 및 사용 방법
|
US20140038842A1
(en)
|
2010-12-28 |
2014-02-06 |
Xoma Technology |
Cell surface display using pdz domains
|
EP2658869B1
(de)
|
2010-12-30 |
2019-06-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenbindende formate zur verwendung in therapeutischen behandlungen oder diagnosetests
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
JP2014502607A
(ja)
|
2011-01-03 |
2014-02-03 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗dig抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
KR101950306B1
(ko)
|
2011-01-14 |
2019-02-20 |
유씨비 바이오파마 에스피알엘 |
Il-17a 및 il-17f에 결합하는 항체 분자
|
US9265887B2
(en)
|
2011-01-24 |
2016-02-23 |
Abbvie Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
EP3763740A1
(de)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
JP6150734B2
(ja)
|
2011-02-03 |
2017-06-21 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
同種移植片の生存を長期化するための抗cd200抗体の使用
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
EP2680925B1
(de)
|
2011-03-02 |
2019-11-20 |
Berg LLC |
Interrogatorische zellbasierte assays und verwendung derselben
|
CA2865487A1
(en)
|
2011-03-07 |
2012-09-13 |
Paula J. Bates |
Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
|
WO2012125735A1
(en)
|
2011-03-15 |
2012-09-20 |
Abott Laboratories |
An integrated approach to the isolation and purification of antibodies
|
AU2012230899A1
(en)
|
2011-03-21 |
2013-10-10 |
Biodesy, Llc |
Classification of kinase inhibitors using nonlinear optical techniques
|
TW201239355A
(en)
|
2011-03-23 |
2012-10-01 |
Abbott Lab |
Methods and systems for the analysis of protein samples
|
EP2691417B1
(de)
|
2011-03-29 |
2018-08-01 |
Roche Glycart AG |
Antikörper-fc-varianten
|
AU2012237287B2
(en)
|
2011-03-30 |
2016-09-08 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against TNF-alpha
|
WO2012134813A1
(en)
|
2011-03-31 |
2012-10-04 |
St. Jude Children's Research Hospital |
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
|
KR20140021589A
(ko)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
항-fgfr4 항체 및 사용 방법
|
JP2014513289A
(ja)
|
2011-04-08 |
2014-05-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
IFNβに対する治療応答性を予測するバイオマーカーおよびその使用
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
US10352936B2
(en)
|
2011-04-14 |
2019-07-16 |
Apoplogic Pharmaceuticals, Inc. |
Use of tumor Fas expression to determine response to anti-cancer therapy
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
EP3103810A3
(de)
|
2011-04-21 |
2017-03-08 |
Garvan Institute of Medical Research |
Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
|
JP2014518624A
(ja)
|
2011-05-12 |
2014-08-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ニューログラニン診断キットのためのアッセイ試薬
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
LT2710035T
(lt)
|
2011-05-16 |
2017-06-26 |
F. Hoffmann-La Roche Ag |
Fgfr1 agonistai ir jų naudojimo būdai
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
WO2012167039A1
(en)
|
2011-06-02 |
2012-12-06 |
Dyax Corp. |
Fc RECEPTOR BINDING PROTEINS
|
BR112013030958B1
(pt)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
AU2012267786B2
(en)
|
2011-06-10 |
2017-08-03 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
CA2838211C
(en)
|
2011-06-10 |
2023-08-01 |
Medimmmune Limited |
Anti-pseudomonas psl binding molecules and uses thereof
|
EP2721067B1
(de)
|
2011-06-15 |
2019-07-31 |
F.Hoffmann-La Roche Ag |
Anti-human-epo-rezeptor-antikörper und verfahren zu deren verwendung
|
JP6113721B2
(ja)
|
2011-06-28 |
2017-04-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
治療標的及び診断標的
|
EA031181B1
(ru)
|
2011-06-28 |
2018-11-30 |
Оксфорд Байотерепьютикс Лтд. |
Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
KR20140061403A
(ko)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
CA2840482C
(en)
|
2011-07-14 |
2018-10-16 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
JP6185463B2
(ja)
|
2011-07-15 |
2017-08-23 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Rspo結合剤およびその使用法
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
UA117220C2
(uk)
|
2011-08-01 |
2018-07-10 |
Дженентек, Інк. |
Способи лікування раку з використанням антагоністів, що зв'язуються з віссю pd-1, і інгібіторів mek
|
EP2756094B1
(de)
|
2011-08-15 |
2017-12-27 |
Medlmmune, LLC |
Anti-b7-h4 antikörper und ihre verwendungen
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
BR112014004213A2
(pt)
|
2011-08-23 |
2017-06-20 |
Found Medicine Inc |
novas moléculas de fusão kif5b-ret e usos das mesmas
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
EP2748200B1
(de)
|
2011-08-23 |
2018-04-11 |
Roche Glycart AG |
Fc-freie antikörper mit zwei fab-fragmenten sowie verwendungsverfahren dafür
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP2753697A1
(de)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
|
CA2848074A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US10093705B2
(en)
|
2011-09-13 |
2018-10-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
EP2771349B1
(de)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatikverfahren zur bestimmung von peptidbindungen
|
AR087918A1
(es)
|
2011-09-19 |
2014-04-23 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
|
TWI583699B
(zh)
|
2011-09-23 |
2017-05-21 |
安可美德藥物股份有限公司 |
Vegf/dll4結合劑類及彼等之用途
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
JP2014531605A
(ja)
|
2011-10-06 |
2014-11-27 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ |
拡張期心不全に関連した方法で使用するためのミオシン結合タンパク質−c
|
CA2851388C
(en)
|
2011-10-10 |
2023-11-21 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
JP6190813B2
(ja)
|
2011-10-14 |
2017-08-30 |
ジェネンテック, インコーポレイテッド |
チモーゲン活性化因子
|
WO2013056054A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc |
Peptide inhibitors of bace1
|
MX2014004426A
(es)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Metodos de uso de antagonistas de scd1.
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
BR112014009799A2
(pt)
|
2011-10-24 |
2017-06-13 |
Abbvie Inc |
imunoligantes dirigidos conra tnf
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
IN2014CN03062A
(de)
|
2011-10-28 |
2015-07-31 |
Hoffmann La Roche |
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773373B1
(de)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Verfahren zur blockierung eines krebsstammzellenwachstums
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
EP3643323A1
(de)
|
2011-11-02 |
2020-04-29 |
University Of Rochester |
Passive immunisierung gegen glucosaminidase für staphylococcus-aureus-infektionen
|
US10527526B2
(en)
|
2011-11-03 |
2020-01-07 |
Tripath Imaging, Inc. |
Methods and compositions for preparing samples for immunostaining
|
WO2013067451A2
(en)
|
2011-11-04 |
2013-05-10 |
Population Diagnostics Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
EP2776065B1
(de)
|
2011-11-07 |
2020-08-05 |
MedImmune Limited |
Kombinationstherapien mit anti-pseudomonas-psl- und pcrv-bindenden molekülen
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
EP2776022A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
EP2776838A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Frühe diagnose neurodegenerativer erkrankungen
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
BR112014011304B1
(pt)
|
2011-11-11 |
2022-03-03 |
UCB Biopharma SRL |
Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
|
AU2012335205A1
(en)
|
2011-11-11 |
2014-05-29 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
KR20140105765A
(ko)
|
2011-11-21 |
2014-09-02 |
이뮤노젠 아이엔씨 |
EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
AU2012340766B2
(en)
|
2011-11-23 |
2018-05-10 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
MX2014006272A
(es)
|
2011-11-23 |
2014-10-24 |
Igenica Biotherapeutics Inc |
Anticuerpos anti-cd98 y metodos de uso de los mismos.
|
US20140017174A1
(en)
|
2011-11-30 |
2014-01-16 |
Raja Atreya |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
EP2788024A1
(de)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antikörper-formulierung
|
EP3800200A1
(de)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
MX356933B
(es)
|
2011-12-14 |
2018-06-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
EP3050900A1
(de)
|
2011-12-19 |
2016-08-03 |
Xoma (Us) Llc |
Verfahren zur behandlung von akne
|
CN113896787A
(zh)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
SG11201403223PA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
MX2014007262A
(es)
|
2011-12-22 |
2014-08-01 |
Hoffmann La Roche |
Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
DK2802606T3
(en)
|
2012-01-10 |
2018-06-25 |
Biogen Ma Inc |
INCREASE TRANSPORT OF THERAPEUTIC MOLECULES OVER THE BLOOD-BRAIN BARRIER
|
PE20141561A1
(es)
|
2012-01-18 |
2014-11-12 |
Genentech Inc |
Anticuerpos anti-lrp5 y metodos de uso
|
EP2804630B1
(de)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von fgf19-modulatoren
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
WO2013120018A1
(en)
|
2012-02-09 |
2013-08-15 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
EP2812350B1
(de)
|
2012-02-11 |
2019-04-03 |
F.Hoffmann-La Roche Ag |
R-spondin-translokationen und verfahren damit
|
EP2814844B1
(de)
|
2012-02-15 |
2017-08-02 |
Novo Nordisk A/S |
Antikörper, die den auslösenden rezeptor binden und blockieren, der auf myeloid-zellen-1 (trem-1) exprimiert ist
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP2814842B1
(de)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antikörper die das peptidoglycan-erkennungs-protein erkennen
|
TR201808458T4
(tr)
|
2012-02-15 |
2018-07-23 |
Hoffmann La Roche |
FC-reseptör bazlı afinite kromatografisi.
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
NZ628804A
(en)
|
2012-02-24 |
2017-08-25 |
Abbvie Stemcentrx Llc |
Dll3 modulators and methods of use
|
PT2825558T
(pt)
|
2012-03-13 |
2019-07-11 |
Hoffmann La Roche |
Terapêutica combinada para o tratamento do cancro do ovário
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
WO2013135745A1
(en)
|
2012-03-16 |
2013-09-19 |
F. Hoffmann-La Roche Ag |
Methods of treating melanoma with pak1 inhibitors
|
EP2825549B1
(de)
|
2012-03-16 |
2018-10-10 |
F. Hoffmann-La Roche SA |
Gleichmässig stabilisierte manipulierte proteine
|
CN104470942B
(zh)
|
2012-03-20 |
2018-12-14 |
奥塔哥创新有限公司 |
生物标志物
|
WO2013139956A1
(en)
|
2012-03-22 |
2013-09-26 |
Thrombogenics Nv |
Antibodies abrogating cell binding to lactadherin
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
BR112014024023A2
(pt)
|
2012-03-28 |
2017-07-18 |
Genentech Inc |
anticorpos idiotípicos anti-hcmv e usos dos mesmos
|
EP2831112A1
(de)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
SG10201608234UA
(en)
|
2012-04-02 |
2016-11-29 |
Berg Llc |
Interrogatory cell-based assays and uses thereof
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
JP6393255B2
(ja)
|
2012-04-20 |
2018-09-19 |
メルス ナムローゼ フェンノートシャップ |
ヘテロ二量体のIgG様分子を生産する方法、ヘテロ二量体のIgG様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
BR112014025560A2
(pt)
|
2012-04-24 |
2017-07-04 |
Thrombogenics Nv |
anticorpos anti-pdgf-c
|
CN106290917B
(zh)
|
2012-04-25 |
2020-06-05 |
比奥德赛公司 |
用于检测蛋白质的变构调节剂的方法
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EA030716B1
(ru)
|
2012-05-14 |
2018-09-28 |
Байоджен Ма Инк. |
Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
|
WO2013172951A1
(en)
|
2012-05-15 |
2013-11-21 |
Morphotek, Inc. |
Methods for treatment of gastric cancer
|
TW201348247A
(zh)
|
2012-05-21 |
2013-12-01 |
Abbvie Inc |
利用蛋白質a親和性層析之非人類抗體之新穎純化
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
CA2874144C
(en)
|
2012-05-31 |
2023-12-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
US20140056890A1
(en)
|
2012-06-06 |
2014-02-27 |
Oncomed Pharmaceuticals, Inc. |
Binding Agents That Modulate the Hippo Pathway and Uses Thereof
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
EP2861624A1
(de)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9-antikörper, formulierungen, dosierung und verfahren zur verwendung
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
US10048253B2
(en)
|
2012-06-28 |
2018-08-14 |
Ucb Biopharma Sprl |
Method for identifying compounds of therapeutic interest
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP3138580B1
(de)
|
2012-07-04 |
2021-03-03 |
F. Hoffmann-La Roche AG |
Kovalent verknüpfte antigen-antikörper-konjugate
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
PL2869837T3
(pl)
|
2012-07-04 |
2017-03-31 |
F.Hoffmann-La Roche Ag |
Przeciwciała przeciw teofilinie i sposoby ich stosowania
|
JP6309518B2
(ja)
|
2012-07-05 |
2018-04-11 |
ジェネンテック, インコーポレイテッド |
発現及び分泌システム
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
EP2869849A1
(de)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunkonjugate mit anti-cd22-antikörpern
|
KR20150030753A
(ko)
|
2012-07-09 |
2015-03-20 |
제넨테크, 인크. |
항-cd79b 항체를 포함하는 면역접합체
|
MX2015000314A
(es)
|
2012-07-09 |
2015-04-10 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados.
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
SI3495387T1
(sl)
|
2012-07-13 |
2021-12-31 |
Roche Glycart Ag |
Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US9297806B2
(en)
|
2012-08-01 |
2016-03-29 |
The Johns Hopkins University |
5-hydroxymethylcytosine in human cancer
|
EP2879710B1
(de)
|
2012-08-03 |
2019-11-13 |
Dana-Farber Cancer Institute, Inc. |
Medizinische verwendungen von immunzellenaktivierungsmodulierenden substanzen und entsprechende screeningverfahren
|
BR112015002681A2
(pt)
|
2012-08-07 |
2018-08-28 |
Genentech Inc |
método para tratar um paciente e kit
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
KR20150046316A
(ko)
|
2012-08-31 |
2015-04-29 |
이뮤노젠 아이엔씨 |
엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
|
US9737493B2
(en)
|
2012-09-07 |
2017-08-22 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for modulating DNMT1 inhibitor activity
|
EP2895621B1
(de)
|
2012-09-14 |
2020-10-21 |
Population Bio, Inc. |
Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
|
WO2014052855A1
(en)
|
2012-09-27 |
2014-04-03 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
EP2904106A4
(de)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zum anzielung von stromazellen zur behandlung von krebs
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
EP2906598A1
(de)
|
2012-10-09 |
2015-08-19 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54-antikörper und verfahren zur verwendung davon
|
BR112015007780A2
(pt)
|
2012-10-09 |
2017-11-28 |
Biogen Idec Inc |
molécula de anticorpo anti-lingo-1, seu uso para tratamento de distúrbios desmielinantes, kit e composição embalada
|
EP3679950A1
(de)
|
2012-10-12 |
2020-07-15 |
The Brigham and Women's Hospital, Inc. |
Verbesserung der immunreaktion
|
JP2015536933A
(ja)
|
2012-10-23 |
2015-12-24 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
|
US20140227252A1
(en)
|
2012-10-31 |
2014-08-14 |
Oncomed Pharmaceuticals , Inc. |
Methods and Monitoring of Treatment with a DLL4 Antagonist
|
TW202014439A
(zh)
|
2012-11-01 |
2020-04-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
AU2013337354A1
(en)
|
2012-11-05 |
2015-05-21 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
WO2014074942A1
(en)
|
2012-11-08 |
2014-05-15 |
Illumina, Inc. |
Risk variants of alzheimer's disease
|
PE20150956A1
(es)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
|
SG11201502876RA
(en)
|
2012-11-08 |
2015-06-29 |
Eleven Biotherapeutics Inc |
Il-6 antagonists and uses thereof
|
EA201590731A1
(ru)
|
2012-11-13 |
2015-11-30 |
Дженентек, Инк. |
Антитела к гемагглютинину и способы применения
|
US10407503B2
(en)
|
2012-11-30 |
2019-09-10 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-Met
|
AU2013359419B2
(en)
|
2012-12-10 |
2018-03-15 |
Biogen Ma Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
KR20150119848A
(ko)
|
2012-12-21 |
2015-10-26 |
바이오얼라이언스 씨.브이. |
친수성 자기-희생 링커 및 그것의 포합체
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
CA2898354C
(en)
|
2013-01-25 |
2017-11-21 |
Thymon, Llc |
Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
|
WO2014121196A1
(en)
|
2013-02-04 |
2014-08-07 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a wnt pathway inhibitor
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
WO2014130923A2
(en)
|
2013-02-25 |
2014-08-28 |
Genentech, Inc. |
Methods and compositions for detecting and treating drug resistant akt mutant
|
CA2896259A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
CA2902263A1
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
CN105229035A
(zh)
*
|
2013-03-11 |
2016-01-06 |
诺和诺德保健股份有限公司 |
生长激素化合物
|
US20160017017A1
(en)
*
|
2013-03-11 |
2016-01-21 |
Novo Nordisk Healthcare Ag |
Growth Hormone Compounds
|
NZ711567A
(en)
|
2013-03-13 |
2020-04-24 |
Genentech Inc |
Antibody formulations
|
RU2707092C2
(ru)
|
2013-03-13 |
2019-11-22 |
Дженентек, Инк. |
Составы со сниженным окислением
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
CA3135558A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Prevention of protein oxidation in a composition
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
AU2014240431A1
(en)
|
2013-03-14 |
2015-08-27 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
CA2906688A1
(en)
|
2013-03-14 |
2014-09-25 |
Parkash S. Gill |
Cancer treatment using antibodies that bind cell surface grp78
|
WO2014158231A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
WO2014143343A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
CN105209076A
(zh)
|
2013-03-15 |
2015-12-30 |
阿布维公司 |
抗体药物偶联物(adc)纯化
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
TWI745671B
(zh)
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
EP2968537A1
(de)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
|
DK2968588T3
(en)
|
2013-03-15 |
2019-04-23 |
Abbvie Deutschland |
ANTI-EGFR ANTIBODY CONJUGATE PHARMACEUTICAL FORMULATIONS
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
SG11201507367PA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Cell culture compositions with antioxidants and methods for polypeptide production
|
KR20150128707A
(ko)
|
2013-03-15 |
2015-11-18 |
제넨테크, 인크. |
간암의 진단 및 치료를 위한 조성물 및 방법
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
SI2970422T1
(en)
|
2013-03-15 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
|
MX2015012326A
(es)
|
2013-03-15 |
2016-03-08 |
Genentech Inc |
Anticuerpos anti-crth2 y su uso.
|
US10160797B2
(en)
|
2013-03-15 |
2018-12-25 |
Sanofi Pasteur Biologics, Llc |
Antibodies against Clostridium difficile toxins and methods of using the same
|
SG11201507333XA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
JP6464145B2
(ja)
|
2013-04-05 |
2019-02-06 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
成長ホルモン化合物製剤
|
US9499621B2
(en)
|
2013-04-08 |
2016-11-22 |
Cytodyn, Inc. |
Felinized antibodies and methods of treating retroviral infections in felines
|
TWI747803B
(zh)
|
2013-04-29 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
人類結合fcrn之經修飾抗體及使用方法
|
EP3327034A1
(de)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-bindungsverhindernde anti-igf-1r-antikörper und ihre verwendung bei der behandlung von vaskulären augenerkrankungen
|
MX2015015060A
(es)
|
2013-04-29 |
2016-02-25 |
Hoffmann La Roche |
Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
|
EP2992331A4
(de)
|
2013-04-30 |
2017-03-29 |
Université de Montréal |
Neuartige biomarker für akute myeloische leukämie
|
EP2981822B1
(de)
|
2013-05-06 |
2020-09-02 |
Scholar Rock, Inc. |
Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
CA2913490A1
(en)
|
2013-06-06 |
2014-12-11 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
CA2914924A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceuticals B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
TW202100181A
(zh)
|
2013-07-16 |
2021-01-01 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CA2919477A1
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
BR112016002008B1
(pt)
|
2013-08-02 |
2021-06-22 |
Pfizer Inc. |
Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
|
EP3030902B1
(de)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
Neues screening-verfahren zur behandlung von friedreich-ataxie
|
DK3036320T3
(da)
|
2013-08-19 |
2021-07-12 |
Biogen Ma Inc |
Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
|
RU2699289C2
(ru)
|
2013-08-26 |
2019-09-04 |
Байонтек Рисерч Энд Дивелопмент, Инк. |
НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
SG11201601416VA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Novel sez6 modulators and methods of use
|
RS62240B1
(sr)
|
2013-08-30 |
2021-09-30 |
Immunogen Inc |
Antitela i testovi za detekciju folatnog receptora 1
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP2848937A1
(de)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
EP3521431A1
(de)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
EP3049437A1
(de)
|
2013-09-27 |
2016-08-03 |
F. Hoffmann-La Roche AG |
Thermus-thermophilus-slyd-fkbp-domänenspezifische antikörper
|
SG11201602283UA
(en)
|
2013-09-27 |
2016-04-28 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
RU2696579C2
(ru)
|
2013-10-08 |
2019-08-05 |
Иммьюноджен, Инк. |
Схемы применения иммуноконъюгата анти-folr1
|
JP2016537965A
(ja)
|
2013-10-11 |
2016-12-08 |
ジェネンテック, インコーポレイテッド |
Nsp4阻害剤及び使用方法
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
MX2016005159A
(es)
|
2013-10-23 |
2016-07-05 |
Genentech Inc |
Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
|
WO2015066027A2
(en)
|
2013-10-28 |
2015-05-07 |
Dots Devices, Inc. |
Allergen detection
|
EP3062884B1
(de)
|
2013-10-29 |
2020-12-02 |
President and Fellows of Harvard College |
Zusammensetzungen zur verwendung in der behandlung von retinitis pigmentosa
|
EP3066123A1
(de)
|
2013-11-07 |
2016-09-14 |
AbbVie Inc. |
Isolierung und reinigung von antikörpern
|
FI3511422T3
(fi)
|
2013-11-12 |
2023-01-31 |
|
Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten
|
ES2720728T3
(es)
|
2013-11-15 |
2019-07-24 |
Pasteur Institut |
Un marcador molecular de Plasmodium falciparum de resistencia a artemisinina
|
RU2697098C1
(ru)
|
2013-11-21 |
2019-08-12 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к альфа-синуклеину и способы применения
|
KR102362803B1
(ko)
|
2013-11-25 |
2022-02-14 |
페임웨이브 리미티드 |
암 치료를 위한 항-ceacam1 및 항-pd 항체를 포함하는 조성물
|
US20160297875A1
(en)
|
2013-12-07 |
2016-10-13 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
BR112016013514B1
(pt)
|
2013-12-13 |
2022-04-19 |
Stora Enso Oyj (Fi) |
Papelão de múltiplas camadas
|
EP3527587A1
(de)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-l1-bindungsantagonisten
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
RU2719487C2
(ru)
|
2013-12-17 |
2020-04-17 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с компонентами сигнального пути pd-1, и таксанов
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
SG11201604815RA
(en)
|
2013-12-19 |
2016-07-28 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
EP2960252A1
(de)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase zur Behandlung von Immunosuppression
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
CN105873616B
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
共价连接的多肽毒素-抗体缀合物
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
CN105873615B
(zh)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
共价连接的helicar-抗helicar抗体缀合物及其用途
|
MX2016008190A
(es)
|
2014-01-06 |
2016-10-21 |
Hoffmann La Roche |
Modulos de lanzadera de barrera cerebral sanguinea monovalente.
|
KR20160107190A
(ko)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10179911B2
(en)
|
2014-01-20 |
2019-01-15 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
UA119863C2
(uk)
|
2014-01-24 |
2019-08-27 |
Нгм Біофармасьютікалс, Інк. |
Антитіло або його фрагмент, що зв'язується з бета-клото
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
US11648335B2
(en)
|
2014-01-31 |
2023-05-16 |
Wake Forest University Health Sciences |
Organ/tissue decellularization, framework maintenance and recellularization
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
EP3102230B1
(de)
|
2014-02-08 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von morbus alzheimer
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
KR102356951B1
(ko)
|
2014-02-11 |
2022-01-27 |
비스테라, 인크. |
뎅기열 바이러스에 대한 항체 분자 및 그의 용도
|
ES2685424T3
(es)
|
2014-02-12 |
2018-10-09 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-Jagged1 y procedimientos de uso
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
WO2015127405A2
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
TWI697500B
(zh)
|
2014-03-14 |
2020-07-01 |
瑞士商諾華公司 |
針對lag-3之抗體分子及其用途
|
CN106103730B
(zh)
|
2014-03-14 |
2021-06-08 |
豪夫迈·罗氏有限公司 |
用于分泌异源多肽的方法和组合物
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
LT3119431T
(lt)
|
2014-03-21 |
2024-03-12 |
Teva Pharmaceuticals International Gmbh |
Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
UA121112C2
(uk)
|
2014-03-31 |
2020-04-10 |
Дженентек, Інк. |
Антитіло до ox40 та його застосування
|
CN113092788A
(zh)
|
2014-04-02 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
检测多特异性抗体轻链错配的方法
|
CN106536556B
(zh)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
结合lgr5的人源化抗体
|
EP3689325A1
(de)
|
2014-04-08 |
2020-08-05 |
Boston Pharmaceuticals Inc. |
Il-21-spezifische bindemoleküle und verwendungen davon
|
TW201542594A
(zh)
|
2014-04-11 |
2015-11-16 |
Medimmune Llc |
雙特異性her2抗體
|
BR112016024319B1
(pt)
|
2014-04-18 |
2024-01-23 |
Acceleron Pharma Inc |
USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
PE20170764A1
(es)
|
2014-04-27 |
2017-07-04 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1)
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
US9753036B2
(en)
|
2014-04-29 |
2017-09-05 |
Edp Biotech Corporation |
Methods and compositions for screening and detecting biomarkers
|
RS61516B1
(sr)
|
2014-04-30 |
2021-03-31 |
Pfizer |
Konjugati anti-ptk7 antitelo-lek
|
RU2713327C2
(ru)
|
2014-05-05 |
2020-02-04 |
Регенерон Фармасьютикалз, Инк. |
Гуманизированные животные по с5 и с3
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びtim−3に対するモノクローナル抗体を用いた癌治療のための併用療法
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
KR20170003582A
(ko)
|
2014-05-22 |
2017-01-09 |
제넨테크, 인크. |
항-gpc3 항체 및 면역접합체
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
JP6894239B2
(ja)
|
2014-05-27 |
2021-06-30 |
アカデミア シニカAcademia Sinica |
増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
RU2636780C1
(ru)
|
2014-06-03 |
2017-11-28 |
ИксБиотеч, Инк. |
КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ ИНФЕКЦИЙ, ВЫЗВАННЫХ Staphylococcus aureus
|
HUE055189T2
(hu)
|
2014-06-04 |
2021-11-29 |
Biontech Res And Development Inc |
Humán monoklonális antitestek a GD2 ganglioziddal ellen
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
TN2016000553A1
(en)
|
2014-06-13 |
2018-04-04 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
KR20170020868A
(ko)
|
2014-06-20 |
2017-02-24 |
바이오얼라이언스 씨.브이. |
항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
WO2016005545A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
WO2016007775A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
EP3169801A1
(de)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostische verfahren und zusammensetzungen zur behandlung von glioblastomen
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
JP6673896B2
(ja)
|
2014-07-15 |
2020-03-25 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びmek阻害剤を使用した癌を処置するための組成物
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
MX2017000484A
(es)
|
2014-07-17 |
2017-05-01 |
Novo Nordisk As |
Mutagenesis dirigida al sitio anticuerpos receptor desencadenante expresado en las celulas mieloides de tipo 1 (trem-1) para reducir la viscosidad.
|
RU2747384C2
(ru)
|
2014-07-21 |
2021-05-04 |
Новартис Аг |
Лечение рака с помощью химерного антигенного рецептора к cd33
|
CN107531800B
(zh)
|
2014-07-25 |
2021-08-10 |
赛拉福柯蒂斯公司 |
用于嵌合抗原受体分子的调控表达的慢病毒载体
|
CA2956991A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
TW202140557A
(zh)
|
2014-08-19 |
2021-11-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
WO2016037157A2
(en)
|
2014-09-05 |
2016-03-10 |
The Johns Hopkins University |
Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
WO2016036403A1
(en)
|
2014-09-05 |
2016-03-10 |
Population Diagnostics Inc. |
Methods and compositions for inhibiting and treating neurological conditions
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
SG10201804931QA
(en)
|
2014-09-12 |
2018-07-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
PE20170935A1
(es)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
US20160137727A1
(en)
|
2014-09-15 |
2016-05-19 |
Genentech, Inc. |
Antibody formulations
|
US10450376B2
(en)
|
2014-09-16 |
2019-10-22 |
Symphogen A/S |
Anti-MET antibodies and compositions
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
US10222386B2
(en)
|
2014-09-19 |
2019-03-05 |
The Johns Hopkins University |
Biomarkers of congnitive dysfunction
|
US10472424B2
(en)
|
2014-09-23 |
2019-11-12 |
Pfizer Inc. |
Treatment with anti-PCSK9 antibodies
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
ES2881575T3
(es)
|
2014-09-30 |
2021-11-29 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts / Univ Heidelberg |
Moléculas de unión, especialmente anticuerpos, que se unen a L1CAM (CD171)
|
TWI707870B
(zh)
|
2014-10-01 |
2020-10-21 |
英商梅迪繆思有限公司 |
針對替格瑞洛的抗體及使用方法
|
ES2774448T3
(es)
|
2014-10-03 |
2020-07-21 |
Novartis Ag |
Terapias de combinación
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
WO2016061460A1
(en)
|
2014-10-17 |
2016-04-21 |
Carnegie Mellon University |
Enhanced biomolecule detection assays based on tyramide signal amplification and gammapna probes
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
WO2016077052A2
(en)
|
2014-10-22 |
2016-05-19 |
President And Fellows Of Harvard College |
Evolution of proteases
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
ES2874331T3
(es)
|
2014-10-24 |
2021-11-04 |
Bristol Myers Squibb Co |
Polipéptidos de FGF-21 modificados y usos de los mismos
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016070051A2
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
EP3223865A4
(de)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Verfahren zur behandlung von erkrankungen mit b7-h4-bindenden antikörpern
|
BR112017009159A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
US10208120B2
(en)
|
2014-11-05 |
2019-02-19 |
Genentech, Inc. |
Anti-FGFR2/3 antibodies and methods using same
|
MX2017005930A
(es)
|
2014-11-05 |
2017-06-30 |
Genentech Inc |
Metodo de produccion de proteinas de cadena doble en bacterias.
|
AU2015343029B2
(en)
|
2014-11-05 |
2021-07-29 |
Annexon, Inc. |
Humanized anti-complement factor C1q antibodies and uses thereof
|
WO2016073794A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
RS59340B1
(sr)
|
2014-11-06 |
2019-10-31 |
Hoffmann La Roche |
Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
SI3215530T1
(sl)
|
2014-11-07 |
2020-02-28 |
Sesen Bio, Inc. |
Izboljšana protitelesa IL-6
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン−33抗体及びその使用
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
WO2016075099A1
(en)
|
2014-11-10 |
2016-05-19 |
Medimmune Limited |
Binding molecules specific for cd73 and uses thereof
|
US20160129108A1
(en)
|
2014-11-11 |
2016-05-12 |
Medimmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
|
CA2967595A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
EP3221360A1
(de)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
US10434177B2
(en)
|
2014-11-17 |
2019-10-08 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
EP3221361B1
(de)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
EP3221364B1
(de)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
CN107108739B
(zh)
|
2014-12-05 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
抗CD79b抗体和使用方法
|
CN107207591A
(zh)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
血脑屏障受体抗体及使用方法
|
PT3333191T
(pt)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
SI3233921T1
(sl)
|
2014-12-19 |
2022-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelesa proti C5 in postopki za uporabo
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
US10221248B2
(en)
|
2014-12-22 |
2019-03-05 |
The Rockefeller University |
Anti-MERTK agonistic antibodies and uses thereof
|
EP3237906B8
(de)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
ES2924394T3
(es)
|
2015-01-09 |
2022-10-06 |
Adalta Ltd |
Moléculas de unión a CXCR4
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
US10342858B2
(en)
|
2015-01-24 |
2019-07-09 |
Academia Sinica |
Glycan conjugates and methods of use thereof
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
EP3250609A4
(de)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra-alpha-2-bindende wirkstoffe und verwendung davon bei der krebsbehandlung
|
JP6942633B2
(ja)
|
2015-01-30 |
2021-09-29 |
アカデミア シニカAcademia Sinica |
抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
|
JP2018507254A
(ja)
|
2015-02-02 |
2018-03-15 |
アイツー ファーマシューティカルズ, インコーポレーテッド |
抗代替軽鎖抗体
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
CA2975525A1
(en)
|
2015-02-04 |
2016-08-11 |
F. Hoffmann-La Roche Ag |
Tau antisense oligomers and uses thereof
|
ES2893114T3
(es)
|
2015-02-04 |
2022-02-08 |
Bristol Myers Squibb Co |
Métodos para seleccionar moléculas terapéuticas
|
KR20170110129A
(ko)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
EP3265491A1
(de)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
|
SG10201907901XA
(en)
|
2015-03-03 |
2019-10-30 |
Kymab Ltd |
Antibodies, uses & methods
|
US20160279207A1
(en)
|
2015-03-10 |
2016-09-29 |
University Of Massachusetts |
Targeting gdf6 and bmp signaling for anti-melanoma therapy
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
JP6944924B2
(ja)
|
2015-03-23 |
2021-10-06 |
ジョンス セラピューティクス, インコーポレイテッド |
Icosに対する抗体
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
WO2016160618A2
(en)
|
2015-03-27 |
2016-10-06 |
University Of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
MY186708A
(en)
|
2015-04-03 |
2021-08-11 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
JP2018514520A
(ja)
|
2015-04-06 |
2018-06-07 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
骨髄非破壊性前処置のための組成物および方法
|
KR20180002659A
(ko)
|
2015-04-06 |
2018-01-08 |
악셀레론 파마 인코포레이티드 |
Tgf-베타 슈퍼패밀리 유형 i 및 유형 ii 수용체 이형다합체들과 이의 용도
|
WO2016164637A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
MX2017013298A
(es)
|
2015-04-13 |
2018-06-19 |
Pfizer |
Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
|
DK3283106T3
(da)
|
2015-04-13 |
2022-01-10 |
Pfizer |
Terapeutiske antistoffer og anvendelser deraf
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
CA2982246A1
(en)
|
2015-04-17 |
2016-10-20 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
EP3285811A1
(de)
|
2015-04-21 |
2018-02-28 |
Institut Gustave Roussy |
Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
EP3286315B1
(de)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Verfahren zur identifizierung von bakterien mit bindenden polypeptiden
|
WO2016172769A1
(en)
|
2015-04-29 |
2016-11-03 |
University Of South Australia |
Compositions and methods for administering antibodies
|
EP3288981A1
(de)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Maskierte anti-cd3-antikörper und verfahren zur verwendung
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
BR112017023829A2
(pt)
|
2015-05-06 |
2018-07-31 |
Janssen Biotech Inc |
agentes de ligação biespecíficos de antígeno de membrana específico da próstata (psma) e usos dos mesmos
|
EA201792451A1
(ru)
|
2015-05-07 |
2018-05-31 |
Агенус Инк. |
Антитела к ox40 и способы их применения
|
EP3936524A3
(de)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
SI3294770T1
(sl)
|
2015-05-12 |
2021-01-29 |
F. Hoffmann-La Roche Ag |
Terapevtski in diagnostični postopki za raka
|
EP4209228A1
(de)
|
2015-05-22 |
2023-07-12 |
Translational Drug Development, LLC |
Benzamid- und wirkstoffzusammensetzungen sowie verfahren zur verwendung
|
WO2016189045A1
(en)
|
2015-05-27 |
2016-12-01 |
Ucb Biopharma Sprl |
Method for the treatment of neurological disease
|
CR20170592A
(es)
|
2015-05-29 |
2018-02-13 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
EP3763827A1
(de)
|
2015-05-29 |
2021-01-13 |
F. Hoffmann-La Roche AG |
Pd-l1-promotormethylierung bei krebs
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
RS60792B1
(sr)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antitela i postupci za njihovu primenu
|
CN107743494B
(zh)
|
2015-06-02 |
2022-04-29 |
诺和诺德股份有限公司 |
具有极性重组延伸体的胰岛素
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CN107847601A
(zh)
|
2015-06-04 |
2018-03-27 |
南加利福尼亚大学 |
Lym‑1和lym‑2靶向的car细胞免疫疗法
|
SG10201911349YA
(en)
|
2015-06-05 |
2020-01-30 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
AR104987A1
(es)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
WO2016205200A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cll-1 antibodies and methods of use
|
LT3310814T
(lt)
|
2015-06-16 |
2023-10-10 |
F. Hoffmann-La Roche Ag |
Humanizuoti ir subrendusio giminingumo antikūnai prieš fcrh5 ir jų naudojimo būdai
|
MX2017016169A
(es)
|
2015-06-17 |
2018-08-15 |
Genentech Inc |
Anticuerpos anti-her2 y metodos de uso.
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
WO2016205681A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
HUE053619T2
(hu)
|
2015-06-29 |
2021-07-28 |
Immunogen Inc |
Anti-CD123 antitestek és konjugátumok és ezek származékai
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
US10392674B2
(en)
|
2015-07-22 |
2019-08-27 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
EP3317301B1
(de)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen lag-3
|
WO2017019895A1
(en)
|
2015-07-30 |
2017-02-02 |
President And Fellows Of Harvard College |
Evolution of talens
|
KR20180035884A
(ko)
|
2015-08-04 |
2018-04-06 |
악셀레론 파마 인코포레이티드 |
골수증식성 장애를 치료하기 위한 방법
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
JP2018532693A
(ja)
|
2015-08-06 |
2018-11-08 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
JP6914919B2
(ja)
|
2015-08-28 |
2021-08-04 |
ジェネンテック, インコーポレイテッド |
抗ヒプシン抗体及びその使用
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
EP3344806A4
(de)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
Glycanarrays und verfahren zur verwendung
|
MX2018003196A
(es)
|
2015-09-15 |
2019-05-16 |
Scholar Rock Inc |
Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
|
RU2749865C2
(ru)
|
2015-09-17 |
2021-06-17 |
Иммьюноджен, Инк. |
Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
|
CN108271372B
(zh)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
EP3352784A4
(de)
|
2015-09-23 |
2019-06-26 |
Cytoimmune Therapeutics, LLC |
Flt3-gerichtete car-zellen zur immuntherapie
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
IL257565B1
(en)
|
2015-09-23 |
2024-04-01 |
Genentech Inc |
Improved variants of anti-VEGF antibodies
|
EP3662930A1
(de)
|
2015-09-24 |
2020-06-10 |
AbVitro LLC |
Hiv-antikörperzusammensetzungen und verfahren zur verwendung
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
MA43348A
(fr)
|
2015-10-01 |
2018-08-08 |
Novo Nordisk As |
Conjugués de protéines
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
CA2997799A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-pd1 antibodies and methods of use
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3365372A1
(de)
|
2015-10-22 |
2018-08-29 |
Jounce Therapeutics, Inc. |
Gensignaturen zur bestimmung der icos-expression
|
RU2022103665A
(ru)
|
2015-10-23 |
2022-03-05 |
Еурека Терапьютикс, Инк. |
Химерные конструкции антитело/t-клеточный рецептор и их применения
|
KR20180067676A
(ko)
|
2015-10-27 |
2018-06-20 |
유씨비 바이오파마 에스피알엘 |
항-il-17a/f 항체를 사용한 치료 방법
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
EP3368157B1
(de)
|
2015-10-29 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
|
CN115160439A
(zh)
|
2015-10-30 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
抗-HtrA1抗体及其使用方法
|
EP3368074A2
(de)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-faktor-d-antikörper und -konjugate
|
GB201519303D0
(en)
|
2015-11-02 |
2015-12-16 |
Imp Innovations Ltd |
Phagemid vector
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
EP3371217A1
(de)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Screening-verfahren für multispezifische antikörper
|
SI3374398T1
(sl)
|
2015-11-10 |
2020-07-31 |
Medimmune, Llc |
Vezavne molekule, specifične za ASCT2 in njihove uporabe
|
AU2016353073A1
(en)
|
2015-11-10 |
2018-06-07 |
Visterra, Inc. |
Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
LT3380522T
(lt)
|
2015-11-25 |
2024-02-26 |
Visterra, Inc. |
Antikūnai prieš april molekules ir jų panaudojimas
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス, インコーポレイテッド |
グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
BR112018003984A2
(pt)
|
2015-12-09 |
2018-09-25 |
Hoffmann La Roche |
anticorpos
|
US10829562B2
(en)
|
2015-12-10 |
2020-11-10 |
Katholieke Universiteit Leuven |
Haemorrhagic disorder due to ventricular assist device
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
PD−1に対する抗体分子とC−Met阻害剤との組合せおよびその使用
|
AU2016372930B2
(en)
|
2015-12-18 |
2020-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies and methods of use
|
WO2017112954A1
(en)
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
CA3007491A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
US20200270365A1
(en)
|
2016-01-05 |
2020-08-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
|
US10287345B2
(en)
|
2016-01-08 |
2019-05-14 |
Scholar Rock, Inc. |
Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
US10472422B2
(en)
|
2016-01-08 |
2019-11-12 |
Abgenomics International Inc. |
Tetravalent anti-PSGL-1 antibodies and uses thereof
|
BR112018014762A2
(pt)
|
2016-01-20 |
2018-12-26 |
Genentech Inc |
método de tratamento da doença de alzheimer (da) precoce
|
WO2017125830A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
|
ES2904593T3
(es)
|
2016-01-21 |
2022-04-05 |
Pfizer |
Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
JP2019509282A
(ja)
|
2016-02-29 |
2019-04-04 |
ファウンデーション・メディシン・インコーポレイテッド |
癌の治療方法
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
SG11201807523PA
(en)
|
2016-03-10 |
2018-09-27 |
Viela Bio Inc |
Ilt7 binding molecules and methods of using the same
|
JP6987072B2
(ja)
|
2016-03-10 |
2021-12-22 |
アクセレロン ファーマ インコーポレーテッド |
アクチビン2型受容体結合タンパク質及びその使用
|
HUE062976T2
(hu)
|
2016-03-11 |
2023-12-28 |
Scholar Rock Inc |
TGFbéta1-hez kötõdõ immunglobulinok és alkalmazásuk
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
ES2831852T3
(es)
|
2016-03-17 |
2021-06-09 |
Univ Oslo Hf |
Proteínas de fusión que se dirigen a macrófagos asociados a tumores para tratar el cáncer
|
EP3433281A1
(de)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispezifische und multifunktionelle moleküle und verwendungen davon
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
CA3018216A1
(en)
|
2016-03-25 |
2017-09-28 |
Visterra, Inc. |
Formulations of antibody molecules to dengue virus
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
KR20180128471A
(ko)
|
2016-03-29 |
2018-12-03 |
얀센 바이오테크 인코포레이티드 |
항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR102486507B1
(ko)
|
2016-04-08 |
2023-01-09 |
아이티아이 헬스, 인크. |
플렉틴-1 결합 항체 및 그의 용도
|
EP3443004A1
(de)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3-antikörper und verfahren zur verwendung
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
EP3443120A2
(de)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Verfahren zur überwachung und behandlung von krebs
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
CN109379889A
(zh)
|
2016-04-22 |
2019-02-22 |
台湾浩鼎生技股份有限公司 |
通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
MA56474A
(fr)
|
2016-05-02 |
2022-05-11 |
Hoffmann La Roche |
Contorsbody - liant de cible à chaîne unique
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
RU2022108606A
(ru)
|
2016-05-16 |
2022-04-11 |
Такеда Фармасьютикал Компани Лимитед |
Антитела к фактору ix padua
|
EP3458101B1
(de)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac-antikörper-konjugate und verfahren zur verwendung
|
CN109415441B
(zh)
|
2016-05-24 |
2023-04-07 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
AU2017274442B2
(en)
|
2016-06-02 |
2021-08-19 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
WO2017211731A1
(en)
|
2016-06-06 |
2017-12-14 |
F. Hoffmann-La Roche Ag |
Fusion proteins for ophthalmology with increased eye retention
|
CN116143918A
(zh)
|
2016-06-24 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
AU2017292646A1
(en)
|
2016-07-05 |
2019-02-07 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
SG11201811704SA
(en)
|
2016-07-13 |
2019-01-30 |
Biogen Ma Inc |
Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
JP2019524721A
(ja)
|
2016-07-15 |
2019-09-05 |
ポセイダ セラピューティクス, インコーポレイテッド |
キメラ抗原受容体および使用方法
|
CN116531490A
(zh)
|
2016-07-15 |
2023-08-04 |
阿塞勒隆制药公司 |
用于治疗肺高血压的组合物和方法
|
CA3027247A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3487880A1
(de)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5(grp78)-antikörper und verwendungen davon
|
KR20190040972A
(ko)
|
2016-07-27 |
2019-04-19 |
악셀레론 파마 인코포레이티드 |
골섬유증 치료 방법 및 조성물
|
US11642400B2
(en)
|
2016-07-27 |
2023-05-09 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
EP3490600A1
(de)
|
2016-08-01 |
2019-06-05 |
Xoma (Us) Llc |
Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
|
EP3494134A1
(de)
|
2016-08-02 |
2019-06-12 |
Visterra, Inc. |
Manipulierte polypeptide und verwendungen davon
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
EP3494139B1
(de)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
|
BR112019002039A2
(pt)
|
2016-08-05 |
2019-05-07 |
Medimmune, Llc |
anticorpos anti-o2 e uso dos mesmos
|
EP3494991A4
(de)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
EP3496763A1
(de)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して免疫障害を治療する方法
|
EP3515932B1
(de)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Auf komplementfaktor basierende affinitätschromatographie
|
AU2017331592A1
(en)
|
2016-09-23 |
2019-04-11 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
MX2019003337A
(es)
|
2016-09-23 |
2019-09-26 |
Teva Pharmaceuticals Int Gmbh |
Tratamiento para migraña refractaria.
|
SI3528838T1
(sl)
|
2016-09-23 |
2023-10-30 |
F. Hoffmann-La Roche Ag |
Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa
|
AU2017331277A1
(en)
|
2016-09-23 |
2019-03-28 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
CN110023304A
(zh)
|
2016-09-28 |
2019-07-16 |
布莱德治疗公司 |
钙蛋白酶调节剂及其治疗用途
|
EP3518969A2
(de)
|
2016-09-28 |
2019-08-07 |
Xoma (Us) Llc |
Antikörper zur bindung von interleukin-2 und verwendungen davon
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
MA46366A
(fr)
|
2016-09-30 |
2019-08-07 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
|
US20180106818A1
(en)
|
2016-10-03 |
2018-04-19 |
Abbott Laboratories |
Methods of assessing gfap status in patient samples
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
WO2018067740A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
TWI775781B
(zh)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
癌症之治療性及診斷性方法
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3526256A1
(de)
|
2016-10-11 |
2019-08-21 |
Agenus Inc. |
Anti-lag-3-antikörper und verfahren zur verwendung davon
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
BR112019007147A2
(pt)
|
2016-10-19 |
2019-06-25 |
Humabs Biomed Sa |
anticorpos anti-o1 e usos dos mesmos
|
US11249082B2
(en)
|
2016-10-29 |
2022-02-15 |
University Of Miami |
Zika virus assay systems
|
US11555076B2
(en)
|
2016-10-29 |
2023-01-17 |
Genentech, Inc. |
Anti-MIC antibodies and methods of use
|
AU2017355402A1
(en)
|
2016-11-02 |
2019-05-30 |
Health Research, Inc. |
Combination treatment with antibody-drug conjugates and PARP inhibitors
|
HUE057559T2
(hu)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
PD-1 elleni antitestek és alkalmazásaik
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
TWI822055B
(zh)
|
2016-11-21 |
2023-11-11 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|
CN110234319B
(zh)
|
2016-11-23 |
2022-09-27 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
TN2019000164A1
(en)
|
2016-11-23 |
2020-10-05 |
Bioverativ Therapeutics Inc |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
KR20230037664A
(ko)
|
2016-12-07 |
2023-03-16 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
AU2017373884A1
(en)
|
2016-12-07 |
2019-05-30 |
Ac Immune Sa |
Anti-tau antibodies and methods of their use
|
AU2017373889A1
(en)
|
2016-12-07 |
2019-06-06 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
WO2018114877A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
In vitro glycoengineering of antibodies
|
EP3559250A1
(de)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Wiederverwendung von enzymen im in-vitro-glyco-engineering von antikörpern
|
BR112019010294A2
(pt)
|
2016-12-21 |
2019-09-03 |
Hoffmann La Roche |
método para a produção enzimática de um anticorpo, anticorpo e formulação farmacêutica
|
KR20190111036A
(ko)
|
2016-12-23 |
2019-10-01 |
비스테라, 인크. |
결합 폴리펩타이드 및 이의 제조 방법
|
JP7198757B2
(ja)
|
2017-01-06 |
2023-01-04 |
スカラー ロック インコーポレイテッド |
ミオスタチン活性化の阻害により代謝疾患を処置するための方法
|
WO2018129329A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
EP3568468A4
(de)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
Gegen histon-h3-peptid/mhc-komplexe gerichtete konstrukte und verwendungen davon
|
CN110312530A
(zh)
|
2017-01-13 |
2019-10-08 |
中央研究院 |
用以治疗心肌梗塞的可重复装载的水胶系统
|
TWI659751B
(zh)
|
2017-01-13 |
2019-05-21 |
中央研究院 |
用以治療腦部疾病之可重複裝載之改良水膠系統
|
CA3049449A1
(en)
|
2017-01-18 |
2018-07-26 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
MX2019008348A
(es)
|
2017-01-18 |
2019-10-21 |
Genentech Inc |
Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
AR111211A1
(es)
|
2017-02-06 |
2019-06-19 |
Australian Meat & Live Stock |
Composiciones inmunoestimulantes y sus usos
|
MA47442A
(fr)
|
2017-02-07 |
2019-12-18 |
Janssen Biotech Inc |
Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
|
MY193457A
(en)
|
2017-02-08 |
2022-10-14 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
CA3051700A1
(en)
|
2017-02-10 |
2018-08-16 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US10765762B2
(en)
|
2017-02-27 |
2020-09-08 |
Regeneron Pharmaceuticals, Inc. |
Humanized model of kidney and liver disorders
|
CN110546277A
(zh)
|
2017-03-01 |
2019-12-06 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
RU2770066C2
(ru)
|
2017-03-02 |
2022-04-14 |
Бет Изрейэл Диконисс Медикал Сентер, Инк. |
Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2018169948A1
(en)
|
2017-03-13 |
2018-09-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
|
TW201842936A
(zh)
|
2017-03-22 |
2018-12-16 |
美商建南德克公司 |
水凝膠交聯化的玻尿酸前藥組合物及方法
|
EP3600442A1
(de)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Optimierte antikörperzusammensetzungen zur behandlung von augenkrankheiten
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
US20200132673A1
(en)
|
2017-03-24 |
2020-04-30 |
The Regents Of The University Of California |
Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
|
CA3056837A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
SG11201908784TA
(en)
|
2017-03-27 |
2019-10-30 |
Hoffmann La Roche |
Improved antigen binding receptor formats
|
JP2020515637A
(ja)
|
2017-04-03 |
2020-05-28 |
オンコロジー、インコーポレイテッド |
免疫腫瘍剤を伴うps標的化抗体を用いる癌の治療方法
|
ES2928718T3
(es)
|
2017-04-03 |
2022-11-22 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
|
CN110494452B
(zh)
|
2017-04-03 |
2023-08-25 |
豪夫迈·罗氏有限公司 |
结合steap-1的抗体
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
EP3606560A2
(de)
|
2017-04-05 |
2020-02-12 |
Novo Nordisk A/S |
Oligomererweiterte insulin-fc-konjugate
|
CN110392698B
(zh)
|
2017-04-05 |
2022-01-25 |
豪夫迈·罗氏有限公司 |
抗lag3抗体
|
JP6997212B2
(ja)
|
2017-04-05 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1及びlag3に特異的に結合する二重特異性抗体
|
JP2020512825A
(ja)
|
2017-04-12 |
2020-04-30 |
ファイザー・インク |
条件的親和性を有する抗体およびその使用の方法
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
KR20200014276A
(ko)
|
2017-04-14 |
2020-02-10 |
가마맵스 파마 |
암을 예방 또는 치료하기 위한 amhrii-결합 화합물
|
US20230227566A1
(en)
|
2017-04-14 |
2023-07-20 |
Gamamabs Pharma |
Amhrii-binding compounds for preventing or treating lung cancers
|
EP3610268A1
(de)
|
2017-04-15 |
2020-02-19 |
Abbott Laboratories |
Verfahren zur unterstützung bei der hyperakuten diagnose und bestimmung von traumatischen hirnverletzungen in einem menschlichen patienten mit frühbiomarkern
|
EP3612563A1
(de)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle und verwendungen davon
|
CA3059615A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
GB201706451D0
(en)
|
2017-04-24 |
2017-06-07 |
Imp Innovations Ltd |
Cancer treatment
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
IL310182A
(en)
|
2017-04-26 |
2024-03-01 |
Eureka Therapeutics Inc ׂ A Delaware Corp |
Structures of chimeric antibody/T-cell receptor and uses thereof
|
KR20200012860A
(ko)
|
2017-04-26 |
2020-02-05 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
US20220135670A1
(en)
|
2017-04-27 |
2022-05-05 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
WO2018200823A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
EP3615566B1
(de)
|
2017-04-28 |
2023-12-20 |
Marengo Therapeutics, Inc. |
Multispezifische moleküle mit einem nicht-immunoglobulin-heterodimerisazionsbereich
|
ES2952961T3
(es)
|
2017-05-01 |
2023-11-07 |
Agenus Inc |
Anticuerpos anti-TIGIT y métodos de uso de los mismos
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
US11168129B2
(en)
|
2017-05-15 |
2021-11-09 |
University Of Rochester |
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
|
EP3630830A1
(de)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Neuer cd73-antikörper, herstellung und verwendungen davon
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
EP3631467A1
(de)
|
2017-05-30 |
2020-04-08 |
Abbott Laboratories |
Verfahren zur hilfe bei der diagnose und evaluierung einer leichten traumatischen hirnläsion bei einer person unter verwendung von herztroponin i
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
CA3062328A1
(en)
|
2017-06-02 |
2018-12-06 |
Pfizer Inc. |
Chimeric antigen receptors targeting flt3
|
KR102356984B1
(ko)
|
2017-06-02 |
2022-01-28 |
화이자 인코포레이티드 |
Flt3에 특이적인 항체 및 이의 용도
|
EP3635007A1
(de)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
|
CA3061959A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP2020525434A
(ja)
|
2017-06-22 |
2020-08-27 |
ムーンショット ファーマ エルエルシー |
アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
|
EP3645042A4
(de)
|
2017-06-26 |
2021-03-17 |
Bio-Techne Corporation |
Hybridom-klone, monoklonale antikörper gegen vsig-4 und verfahren zur herstellung und verwendung
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
US11169159B2
(en)
|
2017-07-03 |
2021-11-09 |
Abbott Laboratories |
Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
|
WO2019010164A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
EVOLUTION OF ARNT SYNTHÉTASES
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
TW201920266A
(zh)
|
2017-07-14 |
2019-06-01 |
美商輝瑞大藥廠 |
Madcam 抗體
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
WO2019018647A1
(en)
|
2017-07-20 |
2019-01-24 |
Pfizer Inc. |
ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
JP2020527351A
(ja)
|
2017-07-21 |
2020-09-10 |
ジェネンテック, インコーポレイテッド |
がんの治療法及び診断法
|
WO2019023661A1
(en)
|
2017-07-28 |
2019-01-31 |
Scholar Rock, Inc. |
SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF
|
KR20200033798A
(ko)
|
2017-08-03 |
2020-03-30 |
알렉터 엘엘씨 |
항-cd33 항체 및 이의 이용 방법
|
TW202246308A
(zh)
|
2017-08-03 |
2022-12-01 |
美商安進公司 |
介白素-21突變蛋白及治療方法
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
WO2019040780A1
(en)
|
2017-08-25 |
2019-02-28 |
Five Prime Therapeutics Inc. |
ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
|
WO2019051424A2
(en)
|
2017-09-08 |
2019-03-14 |
Poseida Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
|
IL272512B
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
WO2019056002A1
(en)
|
2017-09-18 |
2019-03-21 |
President And Fellows Of Harvard College |
CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
AR113142A1
(es)
|
2017-09-29 |
2020-01-29 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
EP3692069A1
(de)
|
2017-10-02 |
2020-08-12 |
Visterra, Inc. |
Antikörpermoleküle gegen cd138 und verwendungen davon
|
EP3692370A2
(de)
|
2017-10-04 |
2020-08-12 |
OPKO Pharmaceuticals, LLC |
Artikel und verfahren zur personalisierten krebstherapie
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
KR20200072507A
(ko)
|
2017-10-19 |
2020-06-22 |
데비오팜 인터네셔날 에스 에이 |
암 치료를 위한 조합 제품
|
EP3697809A1
(de)
|
2017-10-20 |
2020-08-26 |
Institut Curie |
Für rush angepasste dap10/12-basierte cars
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
US20190160089A1
(en)
|
2017-10-31 |
2019-05-30 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
PE20211266A1
(es)
|
2017-10-31 |
2021-07-19 |
Allogene Therapeutics Inc |
Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
BR112020008031A2
(pt)
|
2017-11-01 |
2020-10-27 |
F. Hoffmann-La Roche Ag |
anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
|
EP3704150A1
(de)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Compbody ein multivalentes zielbindemittel
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
CA3082365A1
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
JP2021503478A
(ja)
|
2017-11-16 |
2021-02-12 |
ノバルティス アーゲー |
組み合わせ治療
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
EP3717069A1
(de)
|
2017-11-27 |
2020-10-07 |
Purdue Pharma L.P. |
Gegen menschlichen gewebefaktor gerichtete humanisierte antikörper
|
EP3717517A1
(de)
|
2017-11-30 |
2020-10-07 |
H. Hoffnabb-La Roche Ag |
Anti-pd-l1-antikörper und verfahren zu deren verwendung zum nachweis von pd-l1
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性分子及びその使用
|
EP3721234A1
(de)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
US20210087267A1
(en)
|
2017-12-20 |
2021-03-25 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
EP3729080B1
(de)
|
2017-12-21 |
2023-04-19 |
F. Hoffmann-La Roche AG |
Universelles reporterzellenassay zur spezifitätsprüfung von neuartigen antigenbindenden resten
|
CN111492243A
(zh)
|
2017-12-21 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
用于新颖抗原结合模块的特异性测试的car-t细胞测定法
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
EP4219559A3
(de)
|
2017-12-22 |
2023-10-18 |
Jounce Therapeutics, Inc. |
Antikorper gegen lilrb2
|
US20220135687A1
(en)
|
2017-12-28 |
2022-05-05 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
EP3732202A4
(de)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
Einzeldomänenantikörper und varianten davon gegen tigit
|
CN111886246A
(zh)
|
2017-12-29 |
2020-11-03 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
PE20211270A1
(es)
|
2018-01-12 |
2021-07-19 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento
|
KR20200108868A
(ko)
|
2018-01-12 |
2020-09-21 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-il-8 항체 및 항-pd-1 항체와의 조합 요법
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
JP7268038B2
(ja)
|
2018-01-31 |
2023-05-02 |
アレクトル エルエルシー |
抗ms4a4a抗体及びその使用方法
|
PE20210708A1
(es)
|
2018-02-01 |
2021-04-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
PE20211299A1
(es)
|
2018-02-01 |
2021-07-20 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70
|
CN111868082A
(zh)
|
2018-02-02 |
2020-10-30 |
博奥泰克尼公司 |
调节vista和vsig3的相互作用的化合物及其制备和使用方法
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
AU2019218786A1
(en)
|
2018-02-07 |
2020-07-30 |
Dana-Farber Cancer Institute, Inc. |
Cell-permeable stapled peptide modules for cellular delivery
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
KR102417088B1
(ko)
|
2018-02-09 |
2022-07-07 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
BR112020016400A2
(pt)
|
2018-02-14 |
2020-12-15 |
Viela Bio, Inc. |
Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
|
CN111742219A
(zh)
|
2018-03-01 |
2020-10-02 |
豪夫迈·罗氏有限公司 |
用于新颖靶抗原结合模块的特异性测定法
|
JP2021516051A
(ja)
|
2018-03-02 |
2021-07-01 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
B7−h4抗体及びその使用方法
|
JP2021515770A
(ja)
|
2018-03-05 |
2021-06-24 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il−23特異的抗体を用いたクローン病の治療方法
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
EP3765516A2
(de)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunktionale moleküle und verwendungen davon
|
KR20230020023A
(ko)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
BR112020018918A2
(pt)
|
2018-03-22 |
2021-01-05 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
WO2019190877A1
(en)
|
2018-03-26 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
High throughput method for measuring the protease activity of complement c3 convertase
|
PL3775909T3
(pl)
|
2018-03-26 |
2023-09-18 |
Glycanostics S.R.O. |
Środki i sposoby do profilowania glikozylacji białka
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
US11840568B2
(en)
|
2018-04-02 |
2023-12-12 |
Mab-Venture Biopharm Co., Ltd. |
Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
|
JP2021520209A
(ja)
|
2018-04-04 |
2021-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌患者における腫瘍抗原を検出するための診断アッセイ
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019192973A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
EP3784274A1
(de)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
|
EP3787678A1
(de)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Monoklonale neuraminidase-antikörper gegen influenza und ihre verwendungen
|
US20210171647A1
(en)
|
2018-05-11 |
2021-06-10 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Fully human antibodies against ox40, method for preparing the same, and use thereof
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
CA3100829A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
CA3100828A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
US11319373B2
(en)
|
2018-05-25 |
2022-05-03 |
Alector Llc |
Anti-SIRPA antibodies and methods of use thereof
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
US11913044B2
(en)
|
2018-06-14 |
2024-02-27 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
US11830582B2
(en)
|
2018-06-14 |
2023-11-28 |
University Of Miami |
Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
|
US20210253688A1
(en)
|
2018-06-18 |
2021-08-19 |
UCB Biopharma SRL |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
EP3810269A2
(de)
|
2018-06-19 |
2021-04-28 |
Atarga, LLC |
Antikörpermoleküle zur ergänzung der komponente 5 und deren verwendungen
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
WO2019246557A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
KR20210025614A
(ko)
|
2018-06-29 |
2021-03-09 |
알렉터 엘엘씨 |
항-sirp-베타1 항체 및 그의 사용 방법
|
EP3818083A2
(de)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr-antikörpermoleküle und ihre verwendungen
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
TW202019957A
(zh)
|
2018-07-11 |
2020-06-01 |
美商供石公司 |
TGFβ1抑制劑及其用途
|
HUE056501T2
(hu)
|
2018-07-11 |
2022-02-28 |
Scholar Rock Inc |
Izoforma-szelektív TGF-béta1 inhibitorok és alkalmazásuk
|
WO2020014460A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
|
FI3618928T3
(fi)
|
2018-07-13 |
2023-04-21 |
Alector Llc |
Anti-sortiliini-vasta-aineita ja menetelmiä niiden käyttämiseksi
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
US20200025776A1
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
WO2020033700A1
(en)
|
2018-08-08 |
2020-02-13 |
Pml Screening, Llc |
Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
|
AU2019319822A1
(en)
|
2018-08-08 |
2021-03-18 |
Genentech, Inc. |
Use of tryptophan derivatives and L-methionine for protein formulation
|
EP3833442A2
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antikörper zur bindung von cd277 und verwendungen davon
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833443A1
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigenbindende mittel, die cd277 binden, und verwendungen davon
|
SG11202003531WA
(en)
|
2018-08-10 |
2020-05-28 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
MX2021001672A
(es)
|
2018-08-10 |
2021-07-15 |
Eutilex Co Ltd |
Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
AR119259A1
(es)
|
2018-08-31 |
2021-12-09 |
Alector Llc |
Anticuerpos anti-cd33 y métodos de uso de los mismos
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
US10899826B1
(en)
|
2018-09-13 |
2021-01-26 |
Teva Pharmaceuticals International Gmbh |
Pharmaceutical compositions for an anti-CGRP antagonist antibody
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP4249917A3
(de)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnosemethoden für dreifach-negativen brustkrebs
|
CN113164596A
(zh)
|
2018-09-24 |
2021-07-23 |
詹森生物科技公司 |
用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
|
CA3113826A1
(en)
|
2018-09-27 |
2020-04-02 |
Marengo Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
EP3856773A1
(de)
|
2018-09-28 |
2021-08-04 |
Kyowa Kirin Co., Ltd. |
Il-36-antikörper und verwendungen davon
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
EP3860641A1
(de)
|
2018-10-05 |
2021-08-11 |
Bavarian Nordic A/S |
Kombinationstherapie zur behandlung von krebs mit einer intravenösen verabreichung eines rekombinanten mva und eines immunkontrollpunktantagonisten oder -agonisten
|
MX2021004120A
(es)
|
2018-10-11 |
2021-09-10 |
Pfizer |
Regimen de dosificacion para antagonistas de tfpi.
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
CN113164766A
(zh)
|
2018-10-23 |
2021-07-23 |
供石公司 |
RGMc选择性抑制剂及其用途
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
EP3877407A1
(de)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von zwei kettenproteinen in prokaryotischen wirtszellen
|
SG11202105010UA
(en)
|
2018-11-16 |
2021-06-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies to mucin-16 and methods of use thereof
|
SG11202104918PA
(en)
|
2018-11-20 |
2021-06-29 |
Bavarian Nordic As |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
|
EP3883607A4
(de)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il-23-spezifischem antikörper
|
US20220332800A1
(en)
|
2018-11-20 |
2022-10-20 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
CN113194952A
(zh)
|
2018-12-20 |
2021-07-30 |
诺华股份有限公司 |
Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
JP2022513507A
(ja)
|
2018-12-20 |
2022-02-08 |
ポセイダ セラピューティクス,インコーポレイティド |
ナノトランスポゾン組成物および使用方法
|
EP3898667A2
(de)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modifizierter antikörper fcs und verwendungsverfahren
|
CA3124356A1
(en)
|
2018-12-20 |
2020-06-25 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
EP3898671A1
(de)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
An vegf und il-1beta bindender antikörper und verfahren zur verwendung
|
KR20210107025A
(ko)
|
2018-12-21 |
2021-08-31 |
제넨테크, 인크. |
세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
|
JP2022515473A
(ja)
|
2018-12-28 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質
|
US11447551B2
(en)
|
2018-12-28 |
2022-09-20 |
Sparx Bioscience Limited |
Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
|
JP2022518208A
(ja)
|
2019-01-15 |
2022-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
若年性特発性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
CA3127072A1
(en)
|
2019-01-16 |
2020-07-23 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
AU2020211976A1
(en)
|
2019-01-23 |
2021-07-15 |
Genentech, Inc. |
Methods of producing multimeric proteins in eukaryotic host cells
|
BR112021014267A2
(pt)
|
2019-01-23 |
2022-02-15 |
Janssen Biotech Inc |
Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
WO2020159836A1
(en)
|
2019-01-28 |
2020-08-06 |
Maple Biotech Llc |
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
MX2021009175A
(es)
|
2019-01-30 |
2021-09-14 |
Scholar Rock Inc |
Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
EP3693063A1
(de)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Verfahren und zusammensetzungen zur behandlung von krebs
|
EP3696191A1
(de)
|
2019-02-14 |
2020-08-19 |
Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) |
Car-t-zellen zur behandlung von cd1a-positivem krebs
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
GB2599229A
(en)
|
2019-02-21 |
2022-03-30 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
WO2020172596A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and thereof
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
JP2022526881A
(ja)
|
2019-03-14 |
2022-05-27 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための方法
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
WO2020183269A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
AU2020243588A1
(en)
|
2019-03-18 |
2021-10-07 |
Janssen Biotech, Inc. |
Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
CN113631910A
(zh)
|
2019-03-29 |
2021-11-09 |
豪夫迈·罗氏有限公司 |
细胞表面蛋白质相互作用的调节剂及其相关方法和组合物
|
CA3135430A1
(en)
|
2019-03-29 |
2020-10-08 |
Atarga, Llc |
Anti fgf23 antibody
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
AU2020257748A1
(en)
|
2019-04-19 |
2021-11-18 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor recognizing modification site of antibody
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
CN114206340A
(zh)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
WO2020239558A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
EP3976648A1
(de)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
|
MX2021015212A
(es)
|
2019-06-11 |
2022-04-06 |
Alector Llc |
Anticuerpos antisortilina para uso en terapia.
|
TW202112822A
(zh)
|
2019-06-17 |
2021-04-01 |
美商威特拉公司 |
針對cd138之人類化抗體分子及其用途
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
AU2020323893A1
(en)
|
2019-07-26 |
2022-02-17 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
PE20220487A1
(es)
|
2019-07-31 |
2022-04-04 |
Alector Llc |
Anticuerpos anti-ms4a4a y metodos de uso de los mismos
|
CA3144524A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
PT4007777T
(pt)
|
2019-08-02 |
2024-01-12 |
Hospital CliNic De Barcelona |
Células car t contra bcma para o tratamento de mieloma múltiplo
|
KR102509648B1
(ko)
|
2019-08-06 |
2023-03-15 |
아프리노이아 테라퓨틱스 리미티드 |
병리학적 타우 종에 결합하는 항체 및 이의 용도
|
WO2021023860A1
(en)
|
2019-08-07 |
2021-02-11 |
Db Biotech, As |
Improved horseradish peroxidase polypeptides
|
JP2022545368A
(ja)
|
2019-08-12 |
2022-10-27 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
4-1bbおよび0x40結合タンパク質ならびに関連する組成物および方法、4-1bbに対する抗体、0x40に対する抗体
|
US20210047425A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
JP2022546768A
(ja)
|
2019-09-04 |
2022-11-08 |
ワイ-バイオロジクス・インコーポレイテッド |
抗vsig4抗体または抗原結合フラグメントおよびその使用
|
EP4025303A1
(de)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
|
EP4025593A1
(de)
|
2019-09-05 |
2022-07-13 |
Poseida Therapeutics, Inc. |
Zusammensetzungen allogener zellen und verfahren zur verwendung
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
CA3145940A1
(en)
|
2019-09-16 |
2021-03-25 |
Scott Chappel |
Anti-cd39 antibody compositions and methods
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
JP2022549218A
(ja)
|
2019-09-20 |
2022-11-24 |
ジェネンテック, インコーポレイテッド |
抗トリプターゼ抗体の投薬
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
MX2022003610A
(es)
|
2019-09-27 |
2022-04-20 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
WO2021059075A1
(en)
|
2019-09-27 |
2021-04-01 |
Janssen Biotech, Inc. |
Anti-ceacam antibodies and uses thereof
|
CN114829404A
(zh)
|
2019-10-09 |
2022-07-29 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
MX2022004769A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Inhibidores de tim-3 y sus usos.
|
CA3158298A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
EP4061406A1
(de)
|
2019-11-20 |
2022-09-28 |
Bavarian Nordic A/S |
Rekombinante mva-viren zur intratumoralen und/oder intravenösen verabreichung zur behandlung von krebs
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
CN115151307A
(zh)
|
2019-12-13 |
2022-10-04 |
艾莱克特有限责任公司 |
抗mertk抗体和其使用方法
|
CR20220330A
(es)
|
2019-12-13 |
2022-08-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y métodos de uso.
|
PE20221282A1
(es)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
JP2023507083A
(ja)
|
2019-12-19 |
2023-02-21 |
クイデル コーポレーション |
モノクローナル抗体融合物
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
EP4077389A1
(de)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Kombination des anti-tim-3-antikörpers mbg453 und des anti-tgf-beta-antikörpers nis793 mit oder ohne decitabin oder dem anti-pd-1-antikörper spartalizumab zur behandlung von myelofibrose und des myelodysplastischen syndroms
|
US20230079955A1
(en)
|
2019-12-20 |
2023-03-16 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
PE20221585A1
(es)
|
2019-12-27 |
2022-10-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
TW202136314A
(zh)
|
2020-01-06 |
2021-10-01 |
美商法西尼克斯股份有限公司 |
抗ccr8抗體及其用途
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
JP2023511255A
(ja)
|
2020-01-11 |
2023-03-17 |
スカラー ロック インコーポレイテッド |
TGF-β阻害剤及びその使用
|
JP2023510793A
(ja)
|
2020-01-11 |
2023-03-15 |
スカラー ロック インコーポレイテッド |
TGFβ阻害剤およびその使用
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
IL294388A
(en)
|
2020-01-14 |
2022-08-01 |
Synthekine Inc |
il2 orthologs and methods of use
|
US20230058489A1
(en)
|
2020-01-17 |
2023-02-23 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
IL295387A
(en)
|
2020-02-05 |
2022-10-01 |
Larimar Therapeutics Inc |
Peptide-binding proteins and their uses
|
US20230312704A1
(en)
|
2020-02-10 |
2023-10-05 |
Shanghai Escugen Biotechnology Co., Ltd. |
Cldn18.2 antibody and use thereof
|
KR20220140786A
(ko)
|
2020-02-10 |
2022-10-18 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
클라우딘18.2 항체 및 그것의 사용
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
US20230192900A1
(en)
|
2020-02-13 |
2023-06-22 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
US20230096030A1
(en)
|
2020-02-13 |
2023-03-30 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
US20230125234A1
(en)
|
2020-02-13 |
2023-04-27 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
US20230151109A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
US20230151108A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
CA3166155A1
(en)
|
2020-02-18 |
2021-08-26 |
Spencer LIANG |
Pilra antibodies and methods of use thereof
|
AU2021225920A1
(en)
|
2020-02-28 |
2022-09-15 |
Shanghai Henlius Biotech, Inc. |
Anti-CD137 construct and use thereof
|
CA3169910A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
JP2023516724A
(ja)
|
2020-03-06 |
2023-04-20 |
オーエヌエー セラピューティクス エセ.エレ. |
抗cd36抗体及び癌を治療するためのそれらの使用
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
EP4118107A1
(de)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimäre stimulationsrezeptoren und verfahren zur verwendung bei der t-zell-aktivierung und -differenzierung
|
AU2021233158A1
(en)
|
2020-03-11 |
2022-09-29 |
Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol (Igtp) |
CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
|
CN115605507A
(zh)
|
2020-03-13 |
2023-01-13 |
基因泰克公司(Us) |
抗白介素-33抗体及其用途
|
CN117510630A
(zh)
|
2020-03-19 |
2024-02-06 |
基因泰克公司 |
同种型选择性抗TGF-β抗体及使用方法
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
CN115397850A
(zh)
|
2020-03-30 |
2022-11-25 |
豪夫迈·罗氏有限公司 |
与vegf和pdgf-b结合的抗体及其使用方法
|
EP4126937A1
(de)
|
2020-03-31 |
2023-02-08 |
Alector LLC |
Anti-mertk-antikörper und verfahren zur verwendung davon
|
CA3170570A1
(en)
|
2020-04-01 |
2021-10-07 |
James J. KOBIE |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2021203024A1
(en)
|
2020-04-03 |
2021-10-07 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
AU2021255869A1
(en)
|
2020-04-14 |
2022-10-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for use in the treatment of cancer
|
IL294451A
(en)
|
2020-04-15 |
2022-09-01 |
Hoffmann La Roche |
immune conjugates
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods for using anti-cd79b immunoconjugates
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
WO2021222935A2
(en)
|
2020-04-28 |
2021-11-04 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
EP4143345A1
(de)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
|
CN115461375A
(zh)
|
2020-04-30 |
2022-12-09 |
基因泰克公司 |
Kras特异性抗体及其用途
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
CN115461363A
(zh)
|
2020-05-01 |
2022-12-09 |
诺华股份有限公司 |
免疫球蛋白变体
|
EP4146283A1
(de)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antikörper-wirkstoff-konjugate (adcs) mit einem anti-trop-2-antikörper, zusammensetzungen mit solchen adcs sowie verfahren zur herstellung und verwendung davon
|
WO2021226290A1
(en)
|
2020-05-05 |
2021-11-11 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
JP2023528235A
(ja)
|
2020-05-17 |
2023-07-04 |
アストラゼネカ・ユーケイ・リミテッド |
SARS-CoV-2抗体、並びにこれを選択及び使用する方法
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
US20230220057A1
(en)
|
2020-05-27 |
2023-07-13 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
EP4158058A1
(de)
|
2020-06-02 |
2023-04-05 |
10X Genomics, Inc. |
Anreicherung von nukleinsäuresequenzen
|
AU2021283345A1
(en)
|
2020-06-02 |
2023-02-02 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
US20230235080A1
(en)
|
2020-06-03 |
2023-07-27 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
AU2021288916A1
(en)
|
2020-06-08 |
2022-11-24 |
F.Hoffmann-La Roche Ag |
Anti-HBV antibodies and methods of use
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
MX2022015881A
(es)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
|
JP2023531722A
(ja)
|
2020-06-24 |
2023-07-25 |
ビステラ, インコーポレイテッド |
Aprilに対する抗体分子およびその使用
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
TW202216780A
(zh)
|
2020-07-17 |
2022-05-01 |
美商建南德克公司 |
抗notch2抗體及其使用方法
|
AU2021308586A1
(en)
|
2020-07-17 |
2023-03-02 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
WO2022018040A2
(en)
|
2020-07-20 |
2022-01-27 |
Astrazeneca Uk Limited |
Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same
|
KR20230042032A
(ko)
|
2020-07-21 |
2023-03-27 |
제넨테크, 인크. |
Brm 분해의 항체 접합 화학 유도제 및 이의 방법
|
KR20230040331A
(ko)
|
2020-07-21 |
2023-03-22 |
알로젠 테라퓨틱스 인코포레이티드 |
강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
EP4193149A1
(de)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
|
KR20230048439A
(ko)
|
2020-08-18 |
2023-04-11 |
세파론 엘엘씨 |
항-par-2 항체 및 이의 사용 방법
|
AU2021333779A1
(en)
|
2020-08-26 |
2023-04-13 |
Marengo Therapeutics, Inc. |
Methods of detecting TRBC1 or TRBC2
|
WO2022046922A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204020A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
EP4211166A1
(de)
|
2020-09-11 |
2023-07-19 |
MedImmune Limited |
Therapeutische b7-h4-bindende moleküle
|
IL301264A
(en)
|
2020-09-12 |
2023-05-01 |
Medimmune Ltd |
A scoring method for anti-B7H4 antibody-drug therapy
|
EP3981789A1
(de)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb-antikörper und verwendungen davon
|
AU2021360782A1
(en)
|
2020-10-14 |
2023-06-08 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
WO2022079199A1
(en)
|
2020-10-15 |
2022-04-21 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
KR20230091871A
(ko)
|
2020-10-20 |
2023-06-23 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항제 및 lrrk2 억제제의 병용 요법
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
AR124562A1
(es)
|
2020-10-28 |
2023-04-12 |
Hoffmann La Roche |
Receptores de unión al antígeno mejorada
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
EP4240493A2
(de)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-cd20/anti-cd3-antikörpern und anti-cd79b-antikörper-wirkstoffkonjugaten
|
EP4240758A1
(de)
|
2020-11-04 |
2023-09-13 |
The Rockefeller University |
Neutralisierende anti-sars-cov-2-antikörper
|
EP4251647A1
(de)
|
2020-11-24 |
2023-10-04 |
Bio-Techne Corporation |
Anti-sever-antikörper des akuten atemwegssyndroms coronavirus
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
AU2021390501A1
(en)
|
2020-12-01 |
2023-06-29 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
KR20230117169A
(ko)
|
2020-12-02 |
2023-08-07 |
알렉터 엘엘씨 |
항-소르틸린 항체의 사용 방법
|
US20220177535A1
(en)
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
AU2021398385A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
CN116670166A
(zh)
|
2020-12-07 |
2023-08-29 |
Ucb生物制药有限责任公司 |
多特异性抗体和抗体组合
|
AU2021399841A1
(en)
|
2020-12-17 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
JP2024500747A
(ja)
|
2020-12-18 |
2024-01-10 |
キニクサ ファーマシューティカルズ, リミテッド |
タンパク質組成物ならびにそれを産生及び使用するための方法
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
CN117425501A
(zh)
|
2021-01-13 |
2024-01-19 |
纪念斯隆凯特琳癌症中心 |
抗体-吡咯并苯二氮䓬衍生物缀合物
|
AU2022208361A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Anti-dll3 antibody-drug conjugate
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
TW202245825A
(zh)
|
2021-01-20 |
2022-12-01 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
IL304955A
(en)
|
2021-02-09 |
2023-10-01 |
Us Health |
Antibodies targeting the spike protein of a coronavirus
|
CN117396502A
(zh)
|
2021-02-09 |
2024-01-12 |
佐治亚大学研究基金会有限公司 |
针对肺炎球菌抗原的人类单克隆抗体
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
KR20230157986A
(ko)
|
2021-03-02 |
2023-11-17 |
체게에르페 다이어그노스틱스 게엠베하 |
편투통 발생의 치료 및/또는 저감
|
JP2024512305A
(ja)
|
2021-03-03 |
2024-03-19 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
破骨細胞生成の新規制御因子としてのLaタンパク質
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗bcma抗体を含む抗体-薬物コンジュゲート
|
EP4301786A1
(de)
|
2021-03-03 |
2024-01-10 |
Pierre Fabre Medicament |
Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
|
JP2024509191A
(ja)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗vista構築物およびその使用
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
CA3213278A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
AR125074A1
(es)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4308607A2
(de)
|
2021-03-18 |
2024-01-24 |
MedImmune Limited |
An ccr9 bindendes therapeutisches bindungsmolekül
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
EP4314063A1
(de)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b-antikörper zur behandlung und prävention von coronavirusinfektionen
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
EP4320147A2
(de)
|
2021-04-08 |
2024-02-14 |
Marengo Therapeutics, Inc. |
An tcr bindende multifunktionelle moleküle und verwendungen davon
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
CN117642428A
(zh)
|
2021-05-03 |
2024-03-01 |
Ucb生物制药有限责任公司 |
抗体
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2022245920A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2022256313A1
(en)
|
2021-06-01 |
2022-12-08 |
10X Genomics, Inc. |
Validation of a unique molecular identifier associated with a nucleic acid sequence of interest
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
TW202306994A
(zh)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
抗ddr2抗體及其用途
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CA3216220A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
AU2022299185A1
(en)
|
2021-06-23 |
2024-01-25 |
Scholar Rock, Inc. |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
BR112023023480A2
(pt)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
Uso de anticorpo anti-ctla-4
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
AU2022306973A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
KR20240032991A
(ko)
|
2021-07-09 |
2024-03-12 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 생성을 위한 제조 방법
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
WO2023288267A1
(en)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
WO2023007472A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
CA3227511A1
(en)
|
2021-08-06 |
2023-02-09 |
Lætitia LINARES |
Methods for the treatment of cancer
|
IL310535A
(en)
|
2021-08-10 |
2024-03-01 |
Byomass Inc |
Anti-GDF15 antibodies, compositions and uses thereof
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
WO2023026205A1
(en)
|
2021-08-24 |
2023-03-02 |
Cgrp Diagnostics Gmbh |
Preventative treatment of migraine
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
TW202323289A
(zh)
|
2021-08-31 |
2023-06-16 |
日商大正製藥股份有限公司 |
抗生長激素抗體
|
WO2023031881A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long qt syndrome
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
CA3233506A1
(en)
|
2021-10-04 |
2023-04-13 |
Joseph S. LUCAS |
Transposon compositions and methods of use thereof
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
WO2023058705A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
抗hla-dq2.5抗体の製剤
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
WO2023086824A1
(en)
|
2021-11-10 |
2023-05-19 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2023097254A1
(en)
|
2021-11-24 |
2023-06-01 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
US20240041981A1
(en)
|
2021-12-01 |
2024-02-08 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
WO2023141576A1
(en)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
TW202346365A
(zh)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及化學療法之組合治療
|
WO2023180511A1
(en)
|
2022-03-25 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Improved chimeric receptors
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023196866A1
(en)
|
2022-04-06 |
2023-10-12 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
TW202400637A
(zh)
|
2022-04-25 |
2024-01-01 |
美商威特拉公司 |
April之抗體分子及其用途
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023250402A2
(en)
|
2022-06-22 |
2023-12-28 |
Antlera Therapeutics Inc. |
Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024062038A1
(en)
|
2022-09-21 |
2024-03-28 |
Elthera Ag |
Novel binding molecules binding to l1cam
|